BetaII-spectrin gaps and patches emerge from the patterned assembly of the actin/spectrin membrane skeleton in human motor neuron axons Authors: Nahir Guadalupe Gazal, Maria Jose Castellanos-Montiel, Guillermina Bruno, Anna Kristina Franco-Flores, Sarah Lépine, Lale Gursu, Ghazal Haghi, Gilles Maussion, Wolfgang E Reintsch, Fernando D Stefani, Agustín Anastasía, Mariano Bisbal, Ezequiel Axel Gorostiza, Thomas M Durcan, Nicolás Unsain, Pascal Martin, Nahir Guadalupe Gazal, Maria Jose Castellanos-Montiel, Guillermina Bruno, Anna Kristina Franco-Flores, Sarah Lépine, Lale Gursu, Ghazal Haghi, Gilles Maussion, Wolfgang Reintsch, Fernando D Stefani, Agustín Anastasía, Mariano Bisbal, Ezequiel Axel Gorostiza, Thomas M Durcan, Nicolás Unsain Published: 2026 ABSTRACT The actin/spectrin membrane-associated periodic skeleton (MPS) is a cytoskeletal structure that supports axonal integrity and function. Lower spinal motor neurons (MNs) are characterized by exceptionally long axons and are particularly susceptible to degeneration in a wide range of hereditary neuromuscular disorders, including amyotrophic lateral sclerosis. Using confocal and super-resolution imaging, we characterized the spatial distribution of βII-spectrin and the assembly pattern of the MPS in human MN axons derived from induced pluripotent stem cells. We discovered a striking gap-and-patch pattern in the medial axon, where sharply demarcated βII-spectrin gaps alternate with patches containing a well-organized MPS. The pattern is acutely induced by the kinase inhibitor staurosporine and pharmacological inhibition of actin polymerization prevents patch formation, indicating a requirement for actin nucleation in MPS assembly. Our data supports a model in which spectrin incorporation into nascent MPS patches depletes neighboring regions, producing long-range gaps-and-patches patterns. Introduction The actin/spectrin membrane-associated periodic skeleton (MPS) consists of a periodic arrangement of F-actin rings separated by ∼185 nm α/β-spectrin tetramer spacers, and is present in the axons and dendrites of all neuronal types examined across diverse animal species (Unsain et al., 2018b; Leterrier, 2021). Since its discovery in 2013 (Xu et al., 2013), the MPS has been identified in neurons from the peripheral and central nervous systems of worms, flies, rodents, and humans (D’Este et al., 2016; He et al., 2016). Its phylogenetic conservation is consistent with the fundamental neuronal functions in which it has been implicated. For example, a spectrin-dependent skeleton protects axons from breaking during normal animal movements or under acute stress (Hammarlund et al., 2007; Krieg et al., 2017; Dubey et al., 2020). Additionally, the MPS organizes signaling platforms through the recruitment of signaling receptors (Zhou et al., 2019) and impacts membrane protein diffusion (Albrecht et al., 2016; Rentsch et al., 2024). It can also assemble with myosin to form functional actomyosin complexes, which in turn dynamically alter axon caliber and tension (Berger et al., 2018; Costa et al., 2020; Wang et al., 2020). Furthermore, MPS remodeling has been found to contribute toward axonal breakdown during developmental axon degeneration Unsain et al., 2018a; Wang et al., 2019; for a review, see Costa and Sousa, 2021. Taken together, the evidence suggests that the MPS is critical for preserving the function and structural stability of axons. Lower spinal motor neurons (MNs) are characterized by exceptionally long axons, which can extend thousands of times the diameter of the cell soma. Their somas reside in the anterior horn of the spinal cord, receiving input from upper MNs and projecting axons through peripheral nerves to innervate skeletal muscles, enabling voluntary movement (Stifani, 2014). MN axons are particularly susceptible to structural instability and degeneration in a wide range of hereditary neuromuscular disorders, including amyotrophic lateral sclerosis (ALS). ALS is a neurodegenerative disease characterized by the progressive loss of MNs from the brain cortex, brainstem, and spinal cord. About 90% of ALS cases are sporadic (sALS), while the remaining cases are familial (fALS) (Younger and Brown, 2023). Over 30 genes have been implicated in fALS. Among these, FUS (fused in sarcoma), TARDBP (transactive response DNA-binding protein), and SOD1 (Cu/Zn superoxide dismutase 1) account for approximately 20% of fALS and have also been described in about 5% of sALS (Akçimen et al., 2023). In spite of their clinical relevance, a detailed description of βII-spectrin distribution and MPS organization in MN axons is still incomplete. Spectrin functions as a symmetric hetero tetramer. Dimeric spectrin is formed by the lateral association of α and β monomers in a head-to-tail fashion. Dimers then associate in a head-to-head formation to produce the ∼185-nm-long tetramer. Neurons express a single isoform of α-spectrin (αII) but multiple β-spectrin isoforms (βII, βIII, and βIV), which exhibit distinct subcellular localizations. βII-spectrin predominates in the axonal shaft, βIII-spectrin is enriched in the soma and dendrites, while βIV-spectrin is the exclusive β isoform at the axon initial segment and the node of Ranvier. The MPS is absent in nascent, immature neurites and assembles only after initial neurite extension. Most studies on MPS assembly have been conducted in cultured rat hippocampal neurons, where it was shown that during axon extension the MPS is better organized proximal to the soma, with a seemingly continuous proximal-to-distal gradient of organization, with no evident periodic distribution in the most distal portions. After around 10 days in vitro (DIV), on the other hand, all axonal portions reach a high degree of organization of the MPS (Zhong et al., 2014; Barabas et al., 2017). Recently, it was proposed that this continuous MPS organization arises from the coalescence of discontinuous ‘patches’ of incomplete MPS units that originate in the distal axon and migrate proximally (Hofmann et al., 2022). These patches appear to form from spectrin tetramers accumulating in the growth cone, which then assemble into an incomplete periodic structure. The transport and assembly of spectrin into the MPS have also been studied in mature neurons in situ in Caenorhabditis elegans (Glomb et al., 2023). In this animal model, authors showed that spectrin is actively transported to distal axonal regions via kinesin motors, and that proper MPS assembly and maintenance requires a finely balanced spectrin supply. However, the precise mechanisms governing MPS formation in extending neurites and whether different neuronal types exhibit unique assembly patterns remain poorly understood. In this work, we investigated βII-spectrin distribution and MPS organization and assembly dynamics in human induced pluripotent stem cell (iPSC)-derived MNs (Deneault et al., 2022). Noteworthy, we observed that βII-spectrin and αII-spectrin in distinct axonal sections exhibited sharp, periodic interruptions in their otherwise continuous distribution. These ‘gaps’ were interspersed with ‘patches’ bearing a well-organized MPS, forming a distinct pattern along the axon. The occurrence of axonal sections with βII-spectrin gaps was unrelated to cell stress or caspase/calpain activity, but could be notably induced by the broad kinase inhibitor staurosporine. Using stimulated emission depletion (STED) nanoscopy, we confirmed that the MPS was well preserved within the patches. Analysis of individual axons along their entire length revealed that gaps and patches predominantly occurred in the medial axon. In contrast, spectrin proximal to these regions was continuously distributed with normal MPS organization, whereas the distal region exhibited a sharp reduction in spectrin levels and a lack of an MPS organization. These findings imply that gap and patch formation are correlated: once βII-spectrin is incorporated into a nascent MPS structure, it stops diffusing and accumulates in patches, depleting free βII-spectrin in gaps. In addition, we demonstrated that actin nucleation plays a role in this process, as latrunculin-A treatment prevents the acute effect of staurosporine. Furthermore, we extended our analysis into cellular models of hereditary ALS to assess whether the MPS is similarly organized under pathological conditions. Our findings provide a detailed characterization of βII-spectrin distribution and MPS organization in human neurons and provide new insights into the dynamic assembly of this cytoskeletal structure. Results βII-spectrin is distributed in a proximal to distal gradient in human iPSC-derived MN axons We initiated our study on the distribution and organization of βII-spectrin in axons of human MNs at the single-cell level. At a cell density that sustains healthy development and maturation for 2 weeks, human iPSC-derived MN cultures develop dense axonal areas (Figure 1—figure supplement 1). Although this ‘bulk culture’ approach allows efficient sampling of axonal features, it precludes the tracking of individual axons. To unequivocally trace individual axons from the cell soma to the tip, we seeded cells at low density to obtain sparse neurons and axons. iPSC-derived MNs do not develop properly in low-density cultures and tend to degenerate within the first few days in culture. To overcome this limitation, cells were seeded at high density in the corner of a tilted petri dish and allowed to attach for 2 h (Figure 1—figure supplement 1). After cell attachment, culture dishes were placed flat for 2 weeks under standard conditions. As a result, cells became distributed across the coverslip in a density gradient (‘Density gradient culture’, Figure 1—figure supplement 1). Cells toward the middle of the coverslip are sufficiently spaced to allow individual axons to be unambiguously traced from the soma to the tip (Figure 1C, Figure 1—figure supplement 1). Using quantitative confocal microscopy (see ‘Materials and methods’), we compared the intensities of βII-spectrin in the proximal, medial, and distal portion of axons. To analyze all axons regardless of their length (ranging from 300 to 1000 μm), the first quarter of the axonal length was defined as the proximal segment, the following two quarters were grouped as the medial portion, and the final quarter was designated as distal. We found that βII-spectrin intensity was high in the proximal segment, dropping sharply in the medial region, and decreasing further in the distal region (Figure 1A and B). Qualitatively, the distribution of βII-spectrin presented three noteworthy features: not enriched in axonal tips (which were invariably blunt), was enriched in occasional axonal enlargements, and exhibits portions with a gap-and-patch pattern (insets in Figure 1C, Figure 1—figure supplement 1). All axonal tips lacked an expanded growth cone, and there was no accumulation of βII-spectrin (Figure 1D), in contrast to what is observed in rat hippocampal neurons cultured for 7 days (Figure 1—figure supplement 1; Hofmann et al., 2022). Half of the axons presented axonal enlargements enriched in βII-spectrin (Figure 1E), with a tendency to localize in the medial and distal portions (Figure 1—figure supplement 1). Interestingly, the gap-and-patch patterns were present in about a quarter of the axons examined and were further investigated in bulk cultures to enhance sampling efficiency. βII-spectrin distribution in human iPSC-derived MN axons. (A) Representative βII-spectrin intensity profiles along four individual axons. (B) Mean normalized βII-spectrin intensity in the proximal, medial, and distal portion of 10 axons. Colored traces show the mean normalized values shown in panel (A). ***p<0.001. (C) Representative reconstruction of an individual axon, immunostained for βII-spectrin, NFM, and αII-tubulin. Yellow line highlights the axon being followed. Scale bar = 50 µm. Insets: C1 dashed rectangle highlights a gap-and-patch pattern (*patches), whereas the C2 dashed rectangle highlights axonal enlargements (E) and the axonal tip (T). Scale bar = 10 µm. (D) Representative examples (I–V) of MN axonal tips (T) immunostained for βII-spectrin, βIII-tubulin, and NFH. Scale bar = 10 µm. (E) Representative examples (I–V) of MN axonal enlargements immunostained for βII-spectrin, βIII-tubulin, and NFH. Scale bar = 5 µm. Figure 1—figure supplement 1.Quantitative and qualitative analyses of βII-spectrin distribution in human iPSC-derived MN axons.(A) Representative confocal image of a 2-week-old ‘bulk culture’, immunostained for βII-spectrin. Yellow arrows point to groups of >6 neurons. Red square shows the typical sampling performed to assess axonal features. Scale bar = 50 µm. (B) Schematic representation of the procedure to generate ‘density gradient cultures’. During seeding and the 2 h cell attachment period, culture vials containing coverslips were tilted as shown (top). Culture vials were then placed in a standard upright position for cell maintenance (2 weeks for most experiments, middle). For analyses of whole individual axons, areas toward the middle of the coverslip provided a density that supported healthy neurons while allowing the tracing of single axons (yellow squares, bottom). (C) Representative reconstruction of an individual axon, immunostained for βII-spectrin, βIII-tubulin, and NFH. Yellow line highlights the axon being followed. Scale bar = 50 µm. The C1 dashed rectangle highlights a gap-and-patch pattern (*patches), whereas the C2 dashed rectangle highlights axonal enlargements (E) and the axonal tip (T). Scale bar = 10 µm. (D) Representative images (I–III) of hippocampal neurons grown for 7 DIV and stained for βII-spectrin, 4.1N, and βIII-tubulin. The dashed line contours the expanded growth cone at the tip of the axon, which was delineated using the actin-binding protein 4.1N. Scale bar = 10 µm. (E) Quantification of the number of axonal enlargements in proximal, medial, and distal sections. Quantitative and qualitative analyses of βII-spectrin distribution in human iPSC-derived MN axons. (A) Representative confocal image of a 2-week-old ‘bulk culture’, immunostained for βII-spectrin. Yellow arrows point to groups of >6 neurons. Red square shows the typical sampling performed to assess axonal features. Scale bar = 50 µm. (B) Schematic representation of the procedure to generate ‘density gradient cultures’. During seeding and the 2 h cell attachment period, culture vials containing coverslips were tilted as shown (top). Culture vials were then placed in a standard upright position for cell maintenance (2 weeks for most experiments, middle). For analyses of whole individual axons, areas toward the middle of the coverslip provided a density that supported healthy neurons while allowing the tracing of single axons (yellow squares, bottom). (C) Representative reconstruction of an individual axon, immunostained for βII-spectrin, βIII-tubulin, and NFH. Yellow line highlights the axon being followed. Scale bar = 50 µm. The C1 dashed rectangle highlights a gap-and-patch pattern (*patches), whereas the C2 dashed rectangle highlights axonal enlargements (E) and the axonal tip (T). Scale bar = 10 µm. (D) Representative images (I–III) of hippocampal neurons grown for 7 DIV and stained for βII-spectrin, 4.1N, and βIII-tubulin. The dashed line contours the expanded growth cone at the tip of the axon, which was delineated using the actin-binding protein 4.1N. Scale bar = 10 µm. (E) Quantification of the number of axonal enlargements in proximal, medial, and distal sections. Human iPSC-derived MNs exhibit long axonal sections with sharp interruptions in the distribution of βII-spectrin, creating a gap-and-patch pattern Analyses of βII-spectrin distribution in bulk cultures revealed that a significant proportion of axonal segments exhibited pronounced irregularities, characterized by sharp interruptions, which we termed βII-spectrin ‘gaps’ (βII-spec-gaps) (Figure 2A). Gaps occurred along individual axons in consecutive sequences, forming a gap-and-patch pattern. When comparing the intensity of βII-spectrin in axons without gaps (‘continuous’), within gaps, and within ‘’patches’ (βII-spectrin between gaps), we found that ‘gaps’ had only 20% of the intensity observed in continuous sections, whereas patches presented a similar intensity to that of continuous sections (Figure 2—figure supplement 1). Given these differences, we initially speculated that the gap-and-patch pattern found in certain segments was the end product of a local and spaced depletion of βII-spectrin. Motor neurons present sharp interruptions in the βII-spectrin lattice. (A) Confocal images of bulk cultures immunostained for βII-spectrin. Insets (a–c) show examples of axons with a continuous distribution of βII-spectrin (a and b) and axons with sharp interruptions or ‘gaps’ (asterisks in c and d). Scale bar = 10 µm (left panel) and 5 µm (zoom-in insets). (B) Histograms showing percentual frequency of gaps length, patches length, and gap frequency. (C) Top: representative confocal images of a gap-and-patch pattern co-stained for βII-spectrin, Neurofilament M, and ⍺II-tubulin. Scale bar = 2.5 µm. Bottom: Quantification of intensity ratios. For axons with a continuous βII-spectrin distribution, the ratio of intensity between two regions 5 µm apart was measured (c/c). For axons with βII-spec-gaps, the ratio of intensity between a gap and its flanking patches was measured (g/p). Mean + SEM. t-test. ns: not significant; *p<0.05; ***p<0.001. (D) Top panel: representative confocal images co-stained for βII-spectrin, βIII-tubulin, and Neurofilament H. Scale bar = 2.5 µm. Lower panel: quantification of intensity ratios. For axons with a continuous βII-spectrin distribution, the ratio of intensity between two regions 5 µm apart was measured (c/c). For axons with βII-spec-gaps, the ratio of intensity between a gap and its flanking patch was measured (g/p). Mean + SEM. t-test. ns: not significant; *p<0.05; ***p<0.001. (E) Confocal and differential interference contrast images of axons immunostained for βII-spectrin with a gap-and-patch pattern. Scale bar = 5 µm. Figure 2—figure supplement 1.Axons of human iPSC-derived motor neurons present interruptions in αII-spectrin.(A) Intensity (mean gray values, a.u.) of βII-spectrin and ⍺II-spectrin within regions with continuous distribution (cont.), within gaps, and within patches. (B) Confocal images of bulk cultures immunostained for ⍺II-spectrin. Insets (a–c) show examples of axons with a continuous distribution of βII-spectrin (a and b) and axons with sharp interruptions or ‘gaps’ (asterisks in c and d). Scale bar = 10 µm (left panel) and 5 µm (zoom-in insets). (C) Histograms showing percentual frequency of gaps length, patches length, and gap frequency per 100 µm, in control (DMSO) and staurosporine-treated cells. Axons of human iPSC-derived motor neurons present interruptions in αII-spectrin. (A) Intensity (mean gray values, a.u.) of βII-spectrin and ⍺II-spectrin within regions with continuous distribution (cont.), within gaps, and within patches. (B) Confocal images of bulk cultures immunostained for ⍺II-spectrin. Insets (a–c) show examples of axons with a continuous distribution of βII-spectrin (a and b) and axons with sharp interruptions or ‘gaps’ (asterisks in c and d). Scale bar = 10 µm (left panel) and 5 µm (zoom-in insets). (C) Histograms showing percentual frequency of gaps length, patches length, and gap frequency per 100 µm, in control (DMSO) and staurosporine-treated cells. These βII-spec-gaps had a mean length of 4.56±2.50 μm (mean ± SD) and were spaced by βII-spectrin in ‘patches’ (βII-spec-patches) with a mean length of 3.26±1.46 μm (mean ± SD). In these axons, the gaps-and-patches pattern extended across the entire field of view in most cases, with a gap frequency of 12.13±3.69 every 100 μm (mean ± SD, Figure 2B). In our bulk cultures, in fields of view occupied only by axons, about 15% of axonal segments presented this pattern. A similar pattern of gaps and patches was observed when staining for αII-spectrin, strongly suggesting an absence of MPS in the gaps (Figure 2—figure supplement 1). To assess whether these gaps represented a gross loss of axonal material, we co-stained for constitutive components of the axonal cytoskeleton, with a focus on αII-tubulin, βIII-tubulin, and neurofilament subunits heavy and medium (NF-H and NF-M) (Figure 2C and D). The ratio of intensities between neighboring regions in axons without gaps (continuous axons) allowed us to estimate the variability of these protein distributions (c/c ratios; Figure 2C and D). Based on these findings, we next evaluated the intensity within gaps as a ratio to the neighboring patches. βII-spectrin intensity in gaps was approximately 20–30% of that found in patches (g/p ratios). The distribution of NF-M and NF-H did not change in gaps, while the distribution of αII- and βIII-tubulins showed a drop of 15% and 10%, respectively (Figure 2C and D). Using differential interference contrast (DIC) microscopy, no overt changes in axonal appearance or caliber were noticeable between βII-spec-gaps and the neighboring βII-spec-patches (Figure 2E). Taking into account the continuity and persistence of neurofilament and tubulin isoforms within gaps, as well as the regular appearance of axons under DIC microscopy, we conclude that gaps do not represent axonal interruptions or a gross loss of axoplasm. Axonal segments bearing βII-spectrin gaps increase as a function of weeks in culture and by the acute treatment with staurosporine To gain insight into the mechanisms underlying the formation of βII-spec-gaps, we next investigated conditions that might affect their occurrence. We first observed that the percentage of axonal segments with gaps increased as MNs mature in culture, from 1 to 3 weeks (Figure 3A). Based on earlier observations, these pure MN cultures progressively coalesce into large cell aggregates, eventually detaching from the substrate after continued culture for around 5–6 weeks in vitro (Thiry et al., 2022; Lépine et al., 2024). Presuming that βII-spectrin gaps represent a cytoskeletal rearrangement in response to cellular stress that then leads to detachment, we treated 2-week-old MNs with agents known to induce acute cellular stress: arsenite (Ratti et al., 2020), L-glutamate (Lépine et al., 2024; Shi et al., 2018), and staurosporine (Zhang et al., 2013; Figure 3—figure supplement 1). None of these acute 1-hour treatments induced loss of axons (Figure 3—figure supplement 1). Among them, only staurosporine—a potent, cell-permeable, reversible, ATP-competitive, and broad-spectrum inhibitor of protein kinases (Nakano and Ōmura, 2009)—significantly increased the percentage of axons with gaps (Figure 3B and D). The increase in axons with βII-spec-gaps induced by 1 h of staurosporine treatment was maintained even 24 and 72 h after treatment removal (Figure 3C, Figure 3—figure supplement 1), implying that 1 h of staurosporine produces a persistent effect on the formation of βII-spec-gaps. It is important to note that no appreciable axonal loss was observed at these survival times (Figure 3—figure supplement 1). Apart from their increase in number, βII-spectrin gaps and patches induced by 1 h staurosporine were indistinguishable from those present in vehicle controls (DMSO treated, Figure 3E). Thanks to this, most subsequent analyses were conducted in staurosporine-treated MNs to ensure acute temporal control over the formation of these structures. Staurosporine acutely induces βII-spectrin gaps-and-patches patterns. (A) Graph showing the percentage of axons with βII-spectrin gaps in iPSC-derived MNs cultured for 1, 2, and 3 weeks, and treated for 1 h with vehicle (DMSO). One-way ANOVA, *p<0.05. (B) % of axons with βII-spectrin gaps (normalized to control) in 2-week-old MNs treated for 1 h with arsenite (2 μM), L-glutamate (0.05 mM), and staurosporine (0.1 μM), or the control vehicles, and fixed immediately afterward. One-way ANOVA, *p<0.05. (C) % of axons with βII-spectrin gaps (normalized to time 0) of 2-week-old MNs treated for 1 h with DMSO or staurosporine (0.1 μM) and fixed immediately (0), or 24 and 72 h later. One-way ANOVA, ***p<0.001. (D) Confocal images of 2-week-old MNs treated for 1 h with DMSO or staurosporine (0.1 μM) and immunostained for βII-spectrin and Neurofilament H. Scale bar = 10 μm. (E) Histograms showing percentual frequency of gaps length, patches length, and gap frequency per 100 µm, comparing DMSO and staurosporine. Figure 3—figure supplement 1.Interruptions in βII-spectrin increase as a function of weeks in culture and by acute treatment with staurosporine.(A) Schematic representation of the timeline of the experiments shown in Figure 3B. (B) Total axonal length (a.u.; based on ⍺-tubulin staining) of 2-week-old MNs treated for 1 h with low doses of arsenite (2 μM), L-glutamate (0.05 mM), and staurosporine (0.1 μM), or the control vehicles. ns: not significant. (C) Schematic representation of the timeline of the experiments shown in Figure 3C. (D) Total axonal length (a.u.; based on ⍺-tubulin staining) of 2-week-old MNs treated for 1 h with DMSO or staurosporine (0.1 μM) and fixed immediately (0), or 24 and 72 h later. (E, F) Percentage of axons with βII-spectrin gaps (E) and total axonal length (F, a.u.; normalized to DMSO treatment in each line) of 2-week-old MNs treated for 1 h with DMSO or staurosporine (0.1 μM) and fixed immediately, across the control line (AIW) and lines carrying mutations in ALS-related genes: FUS (H517Q), TDP43/TARDBP (A382T), and SOD1 (G93A and D90A/G93A). *p<0.05; ***p<0.001. Interruptions in βII-spectrin increase as a function of weeks in culture and by acute treatment with staurosporine. (A) Schematic representation of the timeline of the experiments shown in Figure 3B. (B) Total axonal length (a.u.; based on ⍺-tubulin staining) of 2-week-old MNs treated for 1 h with low doses of arsenite (2 μM), L-glutamate (0.05 mM), and staurosporine (0.1 μM), or the control vehicles. ns: not significant. (C) Schematic representation of the timeline of the experiments shown in Figure 3C. (D) Total axonal length (a.u.; based on ⍺-tubulin staining) of 2-week-old MNs treated for 1 h with DMSO or staurosporine (0.1 μM) and fixed immediately (0), or 24 and 72 h later. (E, F) Percentage of axons with βII-spectrin gaps (E) and total axonal length (F, a.u.; normalized to DMSO treatment in each line) of 2-week-old MNs treated for 1 h with DMSO or staurosporine (0.1 μM) and fixed immediately, across the control line (AIW) and lines carrying mutations in ALS-related genes: FUS (H517Q), TDP43/TARDBP (A382T), and SOD1 (G93A and D90A/G93A). *p<0.05; ***p<0.001. Given the clinical relevance of lower MN susceptibility in MN diseases, we sought to determine whether ALS-related mutations influence the percentage of axons exhibiting βII-spectrin gaps. To this end, we differentiated three homozygous knock-in (KI) iPSC lines harboring mutations in FUS (H517Q), TARDBP/TDP43 (A382T), and SOD1 (G93A and D90A/G93A) (Deneault et al., 2022; Lépine et al., 2024) into iPSC-derived MNs and assessed them under basal and staurosporine treatment conditions. Interestingly, the proportion of axons with gaps was similar among the isogenic control (AIW002-02) and the ALS-related mutants under basal conditions. Likewise, staurosporine treatment produced a comparable increase in the proportion of axons with βII-spec-gaps across cell lines (Figure 3—figure supplement 1). Under these conditions, total axonal length remained unchanged (Figure 3—figure supplement 1). These findings indicate that βII-spectrin distribution and its response to staurosporine are unaffected by the presence of ALS-related mutations. βII-spectrin gaps formation is not correlated with proteolytic cleavage of spectrins, nor with the activity of calpains or caspase-3 Spectrins can be cleaved by calpains and caspases, and this processing is modulated during cell remodeling, such as during axon regeneration (Girouard et al., 2018). We hypothesized that regulated activity of these proteases could explain the staurosporine-induced gaps by locally targeting spectrins and disrupting the MPS lattice. Spectrin cleavage products are stable enough to appear as lower molecular weight bands by western blot. To perform this analysis, we treated 2-week-old MNs with vehicle or staurosporine for 1 h, and lysed them either immediately after washout or 6 h later following a medium change (Figure 4—figure supplement 1). First, we performed immunoblot analysis for αII- and βII-spectrin to determine whether spectrins are targeted by proteases during gap formation. Neither αII- nor βII-spectrin showed significant differences between conditions in the full-length band or in the lower molecular weight bands expected as a result of proteolytic cleavage (Figure 4A, Figure 4—figure supplement 1). Thus, neither caspases nor calpains appear to target spectrins during staurosporine-induced gap formation. Proteolytic activity is not likely related to the formation of βII-spectrin gaps. (A) Western blot against βII-spectrin and β-actin in 2-week-old MN cultures from three independent differentiations (batches) treated with vehicle control (DMSO) or staurosporine for 1 h (stau. 1 h), and then either pelleted immediately or 6 h later following a medium change (stau. 1h+6h). (B) Western blot against SNTF (αII-Spectrin N-Terminal Fragment) and β-actin in the same samples as in panel (A). (C, D) Representative images (C) and quantification (D) of βII-spectrin and SNTF in continuous axons (c), in gaps (g), and patches (p) of staurosporine-treated 2-week-old MNs. Two-way ANOVA, ns: not significant. (E, F) Representative images (E) and quantification (F) of βII-spectrin and cleaved-Caspase-3 in continuous axons (c), in gaps (g), and patches (p) of staurosporine-treated 2-week-old MNs. Two-way ANOVA, ***p<0.001. (G) Quantification of axons with βII-spectrin gaps in vehicle (DMSO) and staurosporine-treated 2-week-old MNs with or without the inhibitors for caspase-3 (z-DEVD-fmk) or calpains (ALLN1). One-way ANOVA, ***p<0.001. Figure 4—source data 1.PDF file containing original western blots for Figure 4, indicating the relevant bands and treatments. PDF file containing original western blots for Figure 4, indicating the relevant bands and treatments. Figure 4—source data 2.Original files for western blot analysis displayed in Figure 4. Original files for western blot analysis displayed in Figure 4. Figure 4—figure supplement 1.Proteolytic cleavage of spectrins is not a mechanism that forms gaps in the MPS lattice.(A) Schematic representation of the experimental design and treatment timeline analyzed by western blot (results shown in Figure 4 and in this figure). (B) Quantification of the densitometry of βII-spectrin reactive bands indicated in Figure 4A (*). (C) Quantification of the densitometry of SNTF (αII-Spectrin N-Terminal Fragment) reactive bands indicated in Figure 4B (*). (D) Western blot image against αII-spectrin and β-actin (left) and quantification of the densitometry of reactive bands (*, right). (E) Western blot image against Caspase-3 and β-actin (left) and quantification of the densitometry of reactive bands (*, right). (F) Western blot image against cleaved-Caspase-3 and β-actin (left) and quantification of the densitometry of reactive bands (*, right). Figure 4—figure supplement 1—source data 1.PDF file containing original western blots for Figure 4—figure supplement 1, indicating the relevant bands and treatments. Figure 4—figure supplement 1—source data 2.Original files for western blot analysis displayed in Figure 4—figure supplement 1. Proteolytic cleavage of spectrins is not a mechanism that forms gaps in the MPS lattice. (A) Schematic representation of the experimental design and treatment timeline analyzed by western blot (results shown in Figure 4 and in this figure). (B) Quantification of the densitometry of βII-spectrin reactive bands indicated in Figure 4A (*). (C) Quantification of the densitometry of SNTF (αII-Spectrin N-Terminal Fragment) reactive bands indicated in Figure 4B (*). (D) Western blot image against αII-spectrin and β-actin (left) and quantification of the densitometry of reactive bands (*, right). (E) Western blot image against Caspase-3 and β-actin (left) and quantification of the densitometry of reactive bands (*, right). (F) Western blot image against cleaved-Caspase-3 and β-actin (left) and quantification of the densitometry of reactive bands (*, right). Figure 4—figure supplement 1—source data 1.PDF file containing original western blots for Figure 4—figure supplement 1, indicating the relevant bands and treatments. PDF file containing original western blots for Figure 4—figure supplement 1, indicating the relevant bands and treatments. Figure 4—figure supplement 1—source data 2.Original files for western blot analysis displayed in Figure 4—figure supplement 1. Original files for western blot analysis displayed in Figure 4—figure supplement 1. We further examined these samples with an antibody that recognizes an αII-spectrin fragment produced by calpain cleavage. The SNTF antibody (Spectrin N-Terminal Fragment, Roberts-Lewis et al., 1994) targets a neoepitope of six amino acids at the N-terminus of the stable, calpain-derived ɑII-spectrin fragment of ~150 kDa. We found no consistent changes after 1 h of staurosporine treatment, and highly variable changes 6 h after (Figure 4B, Figure 4—figure supplement 1). Since subtle changes in microdomains can be masked in whole-culture homogenates, we performed quantitative confocal imaging of 1 h staurosporine-treated axons immunostained with anti-SNTF, and compared SNTF signal intensity across continuous axons, and within gaps and patches. Unexpectedly, the SNTF signal in gaps was ~25% lower than in neighboring patches, which is inconsistent with the hypothesis of a local SNTF production in gaps (Figure 4C and D). We conclude that αII-spectrin cleavage—SNTF generation—does not appear to be a relevant feature of gap formation. Caspase-3 is the main executioner caspase in axons, and its active form is generated by cleavage of pro-Caspase-3, a process that can also be followed by western blots. We used two antibodies to detect cleaved-Caspase-3 and found that it was present at very low levels across all treatment conditions. In two of the three batches, both antibodies detected a modest induction of cleaved-Caspase-3, but the levels remained well below what was expected for a global induction by staurosporine (Figure 4—figure supplement 1). To assess this in more detail, we performed confocal imaging of 1 h staurosporine-treated axons immunostained with anti-cleaved-Caspase-3, and compared its intensity in continuous axons, gaps, and patches. We found no significant differences in cleaved-Caspase-3 signals among continuous axons, gaps, and patches (Figure 4E and F). We conclude that the generation of cleaved-Caspase-3 does not appear to be a relevant feature of gap formation. To further assess whether protease activity is required for staurosporine-induced gap formation, we applied a set of validated protease inhibitors. When added 1 h before staurosporine, inhibition of Caspase-3 (z-DEVD-fmk) or calpains (ALLN1) activity failed to alter the induction of axons with gaps (Figure 4G). Taken together, these results suggest that neither the acute, local activity of caspases or calpains nor the degradation of spectrins is necessary for the emergence of MPS gaps. The MPS is absent in βII-spectrin gaps, but it is well organized within patches Confocal imaging allowed us to identify and quantify micrometer-sized gaps and patches in the βII-spectrin lattice within axons of MNs in bulk cultures. However, the resolution achievable through this approach precludes the study of structural features of the MPS. To overcome this, we next used STED nanoscopy to examine the nanoscale organization of βII-spectrin in different regions of these axons. First, we observed that βII-spectrin in axons of 2-week-old MNs exhibited the typical organization of the MPS, and surprisingly, that the MPS was also present in βII-spec-patches—both in vehicle- and staurosporine-treated MNs (Figure 5A). The extent of MPS organization was assessed quantitatively by two methods: (1) the autocorrelation analyses of 2 μm segments, measuring the mean amplitude of the first two peaks of the autocorrelogram (as used elsewhere, Zhong et al., 2014); and (2) the open-source image analysis tool ‘Gollum’, designed for the automated quantification of the quality of protein periodic structures, as detailed in the ‘Materials and methods’ section (Barabas et al., 2017). These measurements confirmed that the MPS is present in both continuous axons (cont.) and in βII-spec-patches (patch, Figure 5B and C), although its organization in the patches tends to be less regular. Interestingly, a 1 h treatment with staurosporine increased the organization in continuous axons (cont., Figure 5C). The MPS is absent in βII-spectrin gaps, but it is well organized within patches. (A) Representative images of βII-spectrin acquired using confocal and STED microscopy in axons with continuous βII-spectrin distribution and in axons with βII-spectrin gaps-and-patches pattern, under both control conditions and acute staurosporine treatment. Scale bars = 1 μm. (B) Autocorrelation amplitude of the intensity profiles along the different regions of interest and treatments. Mean ± SEM. ns: not significant. (C) MPS correlation analyses by Gollum within the different regions of interest and treatments. Mean ± SEM. Two-way ANOVA, ***p<0.001. (D) STED images of double staining for βII-spectrin and F-actin showed the expected anti-phase organization in both continuous axons and patches. Representative images (left) and corresponding intensity profiles between the arrowheads (right). Scale bar = 1 μm. (E) Autocorrelation analyses of βII-spectrin and F-actin in patches and gaps. The traces represent the mean autocorrelation from 17 pairs of patches and gaps. Figure 5—figure supplement 1.The MPS is absent in βII-spectrin gaps, but it is well organized within patches.(A) Representative STED images of αII-spectrin acquired using STED microscopy in axons with continuous αII-spectrin distribution (I–IV) and in axons with αII-spectrin-gaps (V–VIII). Scale bar = 1 μm. (B) Analyses of the percentage of axonal sections that presented a MPS in 2-week-old MNs treated for 1 h with DMSO or staurosporine (0.1 μM) and fixed immediately, across the control line (AIW) and lines carrying mutations in ALS-related genes: SOD1 (D90A/G93A) and TDP43/TARDBP (A382T). Above each bar, the total number of sections analyzed per group is shown. (C, D) Period (C) and autocorrelation amplitude values (D) of MPS axonal sections shown in (B). In (C), values inserted in the graph are the mean value of each group. The MPS is absent in βII-spectrin gaps, but it is well organized within patches. (A) Representative STED images of αII-spectrin acquired using STED microscopy in axons with continuous αII-spectrin distribution (I–IV) and in axons with αII-spectrin-gaps (V–VIII). Scale bar = 1 μm. (B) Analyses of the percentage of axonal sections that presented a MPS in 2-week-old MNs treated for 1 h with DMSO or staurosporine (0.1 μM) and fixed immediately, across the control line (AIW) and lines carrying mutations in ALS-related genes: SOD1 (D90A/G93A) and TDP43/TARDBP (A382T). Above each bar, the total number of sections analyzed per group is shown. (C, D) Period (C) and autocorrelation amplitude values (D) of MPS axonal sections shown in (B). In (C), values inserted in the graph are the mean value of each group. Next, we investigated whether the absence of βII-spectrin in gaps reflects a loss of the underlying MPS, considering that βIII- and βIV-spectrin might replace βII-spectrin and hence allow MPS formation in its absence (Xu et al., 2013; Han et al., 2017). Since actin is a core component of the MPS regardless of the β-spectrin subunit composition, we evaluated whether actin filaments exhibited periodic organization within gaps as an indicator of MPS presence. STED imaging of phalloidin-stained MN axons revealed that actin is periodically organized in ‘continuous’ axons and βII-spect-patches displaying periodic βII-spectrin, consistent with the presence of the MPS (Figure 5D and E). In contrast, periodic F-actin organization was completely absent in the βII-spect-gaps, indicating that these microdomains lack an MPS (Figure 5E). In support of the notion that βII-spec-gaps represent a lack of the MPS, αII-spectrin—another core component of the MPS and the only α-spectrin expressed in neurons—also displayed gaps and patches with a size and frequency distribution similar to those observed for βII-spectrin, suggesting their co-localization (Figure 2—figure supplement 1). Notably, αII-spectrin patches exhibited an MPS structure with a degree of organization comparable to that found in continuous axons (Figure 5—figure supplement 1). We extended these super-resolution analyses to study the MPS on the (KI) iPSC lines harboring mutations in TARDBP/TDP43 (A382T) and SOD1 (D90A/G93A), in comparison to their isogenic control AIW002-02, focusing on axonal sections with a continuous βII-spectrin distribution. We found that between ~80% of regions had an MPS, with no difference among KI lines, and all showing a small increase when treated with staurosporine (Figure 5—figure supplement 1). In MPS-bearing regions, the period found was ~190 nm, with no differences among cell lines or comparing DMSO- or staurosporine-treated (Figure 5—figure supplement 1). Moreover, the extent of organization of the MPS did not show differences among these cell lines and the control line, and while the organization showed a small increase when treated with staurosporine in all lines, this change did not reach statistical significance (Figure 5—figure supplement 1). Taken together, STED nanoscopy enabled the characterization of MPS organization in human iPSC-derived MNs, demonstrating that βII-spectrin-patches contain a well-organized MPS, whereas βII-spect-gaps indeed lack an MPS. Also, ALS-related mutations TARDBP/TDP-43A382T and SOD1-D90A/G93A do not seem to affect MPS presence, period, or organization. Gaps and patches preferentially occur in the middle section of axons We next speculated that determining the proximal-to-distal location of the gap-and-patch pattern, together with a detailed analysis of protein signal intensities along individual axons, could provide insight into the formation of this pattern. We treated ‘density gradient’ cultures with staurosporine for 1 h—to increase the abundance of βII-spectrin gaps—and fixed them immediately afterward. Axons were imaged within 100 μm × 100 μm ROIs, and the number of gaps per section was quantified (Figure 6—figure supplement 1). Under these conditions, 72% of sampled axons presented a gap-and-patch pattern. Among these, the majority (46%) showed gaps exclusively in the medial section, while an additional 15% displayed gaps in both the medial and distal sections (Figure 6A). The graph in Figure 6B shows the number of patches found in each section (normalized by length) for all 26 axons examined, where light gray traces and green dots highlight the axons that presented more gap-and-patches in the medial section. This analysis showed that the gap-and-patch pattern occurs preferentially in the medial section of 2-week-old MN axons. We then investigated whether βII-spectrin intensity along individual axons with a gap-and-patch pattern confined to their middle portion could provide insights into predicting the location of this pattern. To do this, we compared βII-spectrin intensity in gaps and patches with respect to flanking proximal and distal segments, which lacked gaps (Figure 6C). Interestingly, we found that βII-spectrin intensity within patches was similar to that of the nearest proximal continuous section and higher than that of the nearest distal continuous section, whereas intensity within gaps was slightly lower than in the nearest distal continuous section (Figure 6C and D). One possible explanation for the differential concentration of βII-spectrin observed above involves differences in the diffusion rates of ‘free’ vs ‘MPS-bound’ βII-spectrin, as recently demonstrated by in vivo FRAP experiments in C. elegans (Glomb et al., 2023). As patches have an organized MPS, it is reasonable to consider that these patches arise within previously unorganized sections of the axon. Since ‘free’ βII-spectrin incorporated into the forming MPS would stop diffusing, each patch acts as a sink of βII-spectrin. This leads to increased βII-spectrin intensity within patches, and a corresponding depletion in the neighboring regions, which appear as gaps. The resulting gap-and-patch pattern may represent an intermediate stage in the assembly of a mature, long-range MPS lattice. This model accounts for most of the observations presented so far, namely the presence of an MPS in patches (Figure 5A), its absence in gaps (Figure 5D and E), and the microdomain changes in βII-spectrin intensity along axons with a gap-and-patch pattern (Figure 6D). Gaps and patches preferentially occur in the medial portion of axons. (A) Schematic representation of the location of the gaps and patches pattern along individual axons (left) and its observed frequency (right). (B) Normalized number of patches per 100 μm in the proximal, medial, and distal portions. Each trace represents an individual axon. Most axons showed more gaps and patches in the medial portion (light gray traces and green dots), while only a few showed more in the proximal region (dark gray traces and red dots). (C) Schematic (top) and representative confocal images of three βII-spectrin-stained axons with a gap-and-patch pattern confined to the medial sections, showing proximal, medial, and distal sections (bottom). Scale bar = 1 μm. (D) Mean normalized βII-spectrin intensity in the proximal, medial (with gaps and patches pattern), and distal sections. Values were normalized to the proximal intensity of each axon. Colored dots correspond to the three examples shown in panel (C). ns: not significant; *p<0.05; ***p<0.001. Figure 6—figure supplement 1.Gaps and patches preferentially occur in the middle section of axons.(A) Representative axonal reconstructions of two neurons. Numbers along axons indicate approximate distance to the cell soma (μm). Insets show confocal images of proximal, medial, and distal regions, indicated as gray rectangles in the axonal reconstruction, immunostained for βII-spectrin (cyan) and βIII-tubulin (magenta). Scale bar = 1 μm. (B) Quantification of patches length found in vehicle-treated axons (DMSO) and staurosporine-treated 2-week-old MNs with or without the inhibitors for caspase-3 (z-DEVD-fmk) or calpains (ALLN1). In the graph, the values above each bar are the mean length (μm) of each group. One-way ANOVA, *p<0.05, **p<0.01. Gaps and patches preferentially occur in the middle section of axons. (A) Representative axonal reconstructions of two neurons. Numbers along axons indicate approximate distance to the cell soma (μm). Insets show confocal images of proximal, medial, and distal regions, indicated as gray rectangles in the axonal reconstruction, immunostained for βII-spectrin (cyan) and βIII-tubulin (magenta). Scale bar = 1 μm. (B) Quantification of patches length found in vehicle-treated axons (DMSO) and staurosporine-treated 2-week-old MNs with or without the inhibitors for caspase-3 (z-DEVD-fmk) or calpains (ALLN1). In the graph, the values above each bar are the mean length (μm) of each group. One-way ANOVA, *p<0.05, **p<0.01. In line with this conclusion, recent reports show the existence of nascent MPS segments, similar to our ‘patches‘, in distal segments of hippocampal axons in culture (Hofmann et al., 2022; Boyer et al., 2026). In particular, Hofmann and colleagues found that calpain inhibition during axon regeneration did not alter the amount of patches in the new axonal segments, but they suffered a slight increase in their size. Taking this into account, we re-evaluated caspase and calpain inhibition experiments to determine whether protease inhibition altered the length of patches produced during 1 h of staurosporine treatment. We found that staurosporine decreased by approximately ∼10% the length of patches (which agrees with the comparative histograms for patch length shown in Figure 3E), while DEVD and ALLN1 reversed this small change (Figure 6—figure supplement 1). These results can be interpreted in light of limited spectrin disponibility during MPS assembly (i.e., patch formation). On one hand, a limited amount of spectrin makes the extra patches induced during staurosporine treatment to be smaller. On the other hand, protease inhibitors revert that trend by increasing the pool of spectrin availability. Differential MPS organization along axons suggests that patches represent nascent MPS assemblages To validate the hypothesis that the gap-and-patch pattern represents an intermediate stage in the assembly of a mature, long-range MPS lattice, we asked whether the periodical organization of βII-spectrin in the MPS is maintained across the proximal, medial, and distal sections of individual axons exhibiting a gap-and-patch pattern in the medial segment (schematics in Figure 7A). Specifically, we compared MPS correlation coefficients calculated on STED images from the continuous segment in the proximal portion, patches in the middle portion, and the continuous segment in the distal portion along individual axons (Figure 7A). As observed in bulk MN cultures, the patches exhibit an MPS organization comparable to that of the continuous segment in the proximal region (Figure 7A and B). In contrast, the distal portion adjacent to the gap-and-patch pattern lacked an organized MPS (Figure 7A and B). We also noted that patch borders were not sharply defined. Instead, they presented incomplete transverse βII-spectrin labeling while maintaining a longitudinal periodic distribution characteristic of the MPS (Figure 7C and D). Notably, gaps with higher βII-spectrin intensity under confocal imaging showed increased autocorrelation amplitude of this longitudinal periodic arrangement (Figure 7D). Since axons grow by adding membrane at their distal tips (Pfenninger et al., 2003), distal sections represent more recently formed axonal compartments. Taken together, these observations suggest that patches in the medial section represent de novo MPS assembly within previously unorganized, and newer, axonal regions. Patches may represent nascent MPS assemblages. (A) Representative STED images of four individual axons immunostained against βII-spectrin, showing continuous segments in the proximal and distal portions, and patch segments in the medial portions. Scale bar = 1 μm. (B) MPS correlation values of 12 individual axons in the continuous segments of the proximal and distal portions, and patch segments in the medial portion. Colored traces correspond to the axons shown in panel (A). The dashed line at 0.12 indicates the threshold above which a periodic distribution is visually discernible. One-way ANOVA, ns: not significant; ***p<0.001. (C) Representative confocal and STED images of four individual gap-patch borders immunostained for βII-spectrin. White arrowheads indicate the locations of the intensity profiles. Red arrows marked the regions used to calculate the mean period for each section, as shown below. Pink stripes in the background are separated by 200 nm and were drawn for visual reference. Scale bars = 1 μm. (D) Mean autocorrelation curves of longitudinal βII-spectrin structures across sample groups with varying βII-spectrin intensity in the gaps, expressed as a percentage of the intensity found in the neighboring patches. A mean AC curve of patches (gray) is shown for reference. Acute pharmacological sequestration of actin monomers prevents the formation of staurosporine-induced βII-spectrin patches It has been suggested that the nucleation of new actin filaments is important for MPS formation—rather than elongation of existing filaments (Qu et al., 2017). We speculated that staurosporine may induce the gap-and-patch pattern by stimulating the formation of new actin filaments. To acutely interfere with actin polymerization during staurosporine treatment, we used Latrunculin A (LatA, 1 μM), a small molecule known to bind actin monomers and prevent their polymerization into new filaments or incorporation into existing ones (Morton et al., 2000). LatA was added 1 h before staurosporine and remained present during the 1 h staurosporine treatment; cultures were then immediately fixed and immunostained. LatA prevented the staurosporine-induced formation of gaps, without altering the baseline occurrence of gaps in the absence of staurosporine (Figure 8A and B). Quantification of global axonal F-actin staining in these cultures confirmed that treatment with LatA reduced the levels of actin filaments (Figure 8C). On the other hand, staurosporine alone significantly increased the levels of F-actin staining, further supporting the hypothesis that staurosporine stimulates the formation of new actin filaments (Figure 8C). Interestingly, while LatA treatment blocked the formation of staurosporine-induced patches, it did not alter MPS organization in continuous axons with a similar intensity of βII-spectrin or in the preserved patches—likely present before LatA- (Figure 8D and E). These results indicate that, at the dose used, LatA does not disrupt existing MPS structures, but only the generation of new MPS segments. Latrunculin A prevents staurosporine-induced gaps-and-patches pattern formation. (A) Representative confocal images of 2-week-old MNs treated with vehicle (DMSO or EtOH + DMSO), latrunculin A (LatA), staurosporine (Stauro), or latrunculin A+staurosporine (LatA + Stauro). Cells were immunostained for βII-spectrin, α-tubulin, and F-actin (phalloidin). Scale bar = 20 μm. (B) Percentage of axons with βII-spectrin gaps in 2-week-old MNs treated groups shown in panel (A). Mean ± SEM. *p<0.05. Tukey post hoc test. (C) Normalized percentage of F-actin intensity in 2-week-old MNs treated groups shown in panel (A). Mean ± SEM. *p<0.05, ***p<0.001. Tukey post hoc test. (D) Representative STED images of MNs treated with vehicle (DMSO), staurosporine alone (Stauro), latrunculin A alone (LatA), or latrunculin-A+staurosporine (LatA + Stauro), and immunostained for βII-spectrin. Two examples are shown for continuous axonal sections (top rows) and for patches (bottom rows). Scale bar = 1 μm. (E) MPS correlation analyses by Gollum within the different regions of interest and treatments shown in panel (D) (C: continuous, P: patches). ns: not significant. Mean ± SEM. Discussion In this study, we provide a detailed characterization of the spatial organization of βII-spectrin and the MPS in human iPSC-derived MNs. Using confocal imaging, we identified the existence of sharply demarcated interruptions in the otherwise continuous βII-spectrin lattice, forming a distinctive gap-and-patch pattern along axons. These interruptions, or ‘gaps’, which also lack αII-spectrin, occur interspersed with patches where the MPS is well preserved. The formation of βII-spectrin gaps increases with culture duration and can also be acutely induced by the kinase inhibitor staurosporine. Importantly, we showed that the gap-and-patch pattern is not linked to axonal degeneration or cytoskeletal disassembly but may instead reflect a dynamic and spatially regulated process of MPS formation and maturation. Additionally, we demonstrate that pharmacological inhibition of actin polymerization blocks gap formation and further propose that actin nucleation is required for the initial MPS assembly. To our knowledge, this is the first detailed study to map the distribution and organization of βII-spectrin and the MPS along human MN axons at nanoscale resolution—the existence of the MPS in human iPSC-derived MNs was briefly described previously (He et al., 2016). MN axons are the target of dysfunction and degeneration in various neurological conditions and neurodegenerative diseases. Because active remodeling of the MPS has been described in degenerating axons (Unsain et al., 2018a; Wang et al., 2019) and various ALS-related genes directly affect cytoskeletal dynamics (Castellanos-Montiel et al., 2020), we expected that a better understanding of the actin/spectrin cytoskeleton in MN axons could provide clues regarding their vulnerability. Notably, we observed that ALS-related mutations in SOD1, TARDBP/TDP43, and FUS do not significantly affect either the baseline occurrence of βII-spectrin gaps or their induction by staurosporine, suggesting that the normal assembly process of the MPS is preserved in these disease models. In previous reports, we have shown that human iPSC-derived MNs bearing ALS-related mutations exhibit certain disease phenotypes only when maintained in culture for extended periods (Deneault et al., 2022; Lépine et al., 2024), raising the question of how the MPS behaves in neurons cultured for longer periods. A more detailed analysis to determine whether MPS stability is altered in disease-relevant contexts should be examined in the future. Initially, we speculated that the appearance of gaps could result from MPS disassembly via localized proteolytic degradation of its key components. Caspases and calpains are known to cleave spectrins during neuronal injury and axon degeneration (Zhang et al., 2009; Kobeissy et al., 2015), as well as during normal cell remodeling (Lee et al., 2001; Glantz et al., 2007; Girouard et al., 2018). However, our western blot and immunofluorescence analyses revealed no consistent increase in spectrin cleavage products, nor in markers of caspase or calpain activity during staurosporine-induced gap formation. Moreover, the use of pharmacological inhibitors of these proteases failed to prevent the formation of gaps-and-patches patterns. These results argue against the involvement of protease-mediated spectrin degradation that could explain the formation of gaps. On the contrary, our data implies that βII-spectrin patches represent nascent MPS assemblies arising from previously unstructured spectrin-actin complexes along newer axonal domains. In line with this hypothesis, others have recently described the appearance of short MPS segments in medial and distal portions of hippocampal axons in culture (Hofmann et al., 2022; Boyer et al., 2026). On the possible role of proteases in such structures, Hofmann and colleagues found that acute treatment with calpain inhibitors right before axotomy led to an increase in the percentage of periodic spectrin (referred to by authors as ‘periodicity’) in the regenerated axons in a 2 h period. Interestingly, the spectrin patches did not increase in number, but they increased in size. This indicates that in the particular situation of axonal regeneration, calpain activity puts a brake on MPS formation within patches. When we thus examined staurosporine-patches in the presence of caspase and calpain inhibitors, we found that these prevented the slight drop in size produced by staurosporine. We conclude that indeed protease inhibitors have an impact on patch dynamics, likely by changing the availability of spectrins. However, in our case, this effect was considerably smaller than the one observed in regenerated axons (changes of ∼10% vs ∼100%, respectively). Calpain and caspase activity have been shown to be relevant in other aspects of MPS biology (Heller et al., 2025; Fei et al., 2026). Heller and colleagues found that calpain activity contributes to the steady-state dynamics of spectrin exchange in a mature MPS lattice. More recently, Fei and colleagues describe a relevant role for calpains whenever massive endocytosis (of any kind) is engaged experimentally. Interestingly, all these studies, including ours, examined calpains' roles in MPS in different scenarios. Altogether, these results are not contradictory among them and provide valuable complementary information about the roles of calpains (and caspases) in MPS assembly, growth, maintenance, and remodeling. Our detailed super-resolution analyses further support the notion that the patches represent nascent MPS stretches. In axons displaying a medial gap-and-patch pattern, MPS organization was robust in both the proximal region and in the patches, but absent in the distal axon. Interestingly, the borders of patches often displayed an incomplete transverse coverage of βII-spectrin while maintaining longitudinal periodicity, suggestive of a transitional assembly zone. In support of this model, we observed that patches had βII-spectrin levels similar to proximal continuous regions. In turn, accumulation of spectrin within patches depletes surrounding regions and as a result gaps are evidenced between patches: transported spectrin could be locally sequestered into the nascent MPS in patches, which halts its diffusion and effectively depletes the surrounding axonal domains—and gaps emerge. This is consistent with recent in vivo data in C. elegans and hippocampal neurons in culture showing that spectrin diffusion is halted upon incorporation into the MPS (Glomb et al., 2023; Boyer et al., 2026). This dynamic mechanistic model can explain the appearance of a long gap-and-patch pattern found in relatively new portions of the axon. The validity of such a model could be further supported by live-imaging approaches with a tight control of expression levels of tagged βII-spectrin, as was recently developed in the mouse (Heller et al., 2025). Previous work in rodent hippocampal neurons has described the progressive maturation of the MPS in developing axons (Hofmann et al., 2022; Zhong et al., 2014), and the mechanistic details of its initial assembly are beginning to be elucidated (Bodas et al., 2025; Boyer et al., 2026). All these studies, including the present one, agree on the initial observation by Zhong and colleagues that extending axons in culture have a better organized MPS proximal to the cell soma and decrease gradually in moving toward the distal portions. Upon this observation, authors initially implied that new MPS segments were simply being added to the existing MPS in a proximal-to-distal fashion (Hofmann et al., 2022; Zhong et al., 2014). However, this mechanism of MPS growth was later challenged by the observation that in distal regions devoid of a continuous MPS, βII-spectrin accumulations, called ‘patches’, represent immature MPS structures (Hofmann et al., 2022). Given these ‘patches’ increase in size and periodical organization in a distal-to-proximal fashion, it had been proposed that new MPS segments would coalesce with older segments, giving rise to a continuous MPS. The ‘patches’ described by Hofmann and colleagues in hippocampal neurons differ from the ones found by us in MNs in at least two major aspects. First, patches reported by us, once noticeable by confocal microscopy, have a complete MPS organization (i.e., periodic βII-spectrin occupies the complete width of the axon), whereas those described by Hofmann and colleagues do not cover the entire width and resemble the structures we found in the gap-patch borders. Second, the patches described by us in MNs arise in a gap-and-patch pattern, whereas patches shown by Hofmann and colleagues seemed to be isolated features. It is possible that axon extension rate and MPS components synthesis and trafficking rates can explain the differences observed in these cell types. However, it is worth mentioning that the observations by Hofmann and colleagues were performed in methanol-fixed cells, whereas ours were fixed in paraformaldehyde-sucrose in PBS. It is possible that some membrane-bound cytoskeletal assemblages are more noticeable in methanol fixation since it removes ‘unbound’ components. While this manuscript was in preparation, a preprint was published showing a similar gap-and-patch pattern as the ones found by us, but in hippocampal cells (Boyer et al., 2026). However, this report suggests that the patches have no MPS structure, but rather an amorphous condensate of spectrins. On the other hand, we suggest that all three studies have found amorphous, spectrin-rich structures that may serve as a reservoir of spectrin tetramers that later diffuse and incorporate into the MPS. These structures that we suggest to have equivalent functions are: the accumulation of spectrin found in the growth-cone center (Hofmann et al., 2022), the ‘patches’ in the axonal shaft (Boyer et al., 2026), and axonal enlargements shown here (Figure 1). Further experiments would be needed to confirm this proposed function and equivalence of these structures. Taken together, in spite of the above-mentioned differences, all three studies agree that the MPS grow by the maturation of ‘patches’ of MPS/spectrin that then coalesce with the existent, continuous proximal MPS by lateral growth. We further showed that preventing actin polymerization by sequestering G-actin with LatA prevents the formation of staurosporine-induced βII-spectrin patches without affecting the structure of pre-existing MPS regions. This indicates that the formation of the gap-and-patch pattern requires the assembly of actin filaments. The importance of actin dynamics for MPS stability was suggested many times using pharmacological interventions (Zhong et al., 2014; Leterrier et al., 2015; Unsain et al., 2018a; Abouelezz et al., 2019), and work in the fruit fly incorporated genetic approaches to highlight the particular importance of actin nucleation (Qu et al., 2017). While this manuscript was in preparation, a preprint was published in sensory neurons in culture supporting the notion that actin nucleation is necessary for MPS initiation (Bodas et al., 2025). These studies and our own results (Figure 8) have shown that the actin filaments in the MPS are particularly resistant to drugs that alter filament extension, suggesting that their turnover is relatively low compared to other F-actin structures present in the axon. Most F-actin is lost upon sequestration of G-actin for 2 h (by LatA), indicative of their high turnover—as a filament continues to lose monomers from the pointed-end but fails to incorporate monomers at the barbed-end, the filament gets shorter and can eventually disappear. The time frame of this process is indicative of its turnover rate. On the other hand, 2 h of LatA did not alter the MPS, indicating that F-actin in the MPS suffers negligible or no turnover during the 2 h period. Taken together, these reports and our findings suggest that actin filaments within the MPS are stable, and that new MPS segments require the polymerization of new actin filaments. A striking observation in our study is the induction of βII-spectrin gaps by the broad-spectrum kinase inhibitor staurosporine. Apart from the number and a small decrease in patch length, we could not find any other distinction between gaps-and-patches found in untreated cells and in cells treated acutely with staurosporine, so we have assumed that both features are essentially the same objects of study. However, as a caution note for any conclusion driven from negative data, we cannot rule out the possibility that these objects are essentially different from one another. In the meantime, we believe that the treatment with staurosporine is very useful experimentally because it allows for a tight temporal control of gaps-and-patches formation. The effect of staurosporine is robust and persists for at least 72 h, suggesting the engagement of a lasting remodeling process rather than a transient perturbation. Staurosporine has been previously shown to promote neurite outgrowth, actin reorganization, and lamellipodial activity in several neuronal systems (Rasouly et al., 1992; Jalava et al., 1993; Sano et al., 1994; Kohno et al., 2015). Although initially described as a PKC inhibitor, most of these effects seem independent of this master kinase. Based on our findings that latrunculin A (LatA) can prevent staurosporine-induced gaps, we hypothesize that staurosporine may directly or indirectly promote actin filament nucleation. One potential mechanism is the inhibition of LIM kinase 1 (LIMK1), a kinase that phosphorylates and inactivates ADF/cofilin. Dephosphorylated cofilin enhances actin filament turnover and can paradoxically increase total F-actin by generating new barbed ends for filament elongation (Mannherz et al., 2006). Therefore, staurosporine-induced cofilin activation could drive the formation of nascent MPS (patches) by stimulating the extension of new actin filaments. Furthermore, phosphorylation of βII-spectrin and adducin has been implicated in weakening the spectrin-actin network (Manno et al., 1995; Matsuoka et al., 1998; Bignone et al., 2007); hence, it is possible that staurosporine could indirectly stabilize nascent MPS structures by direct inhibition of the kinases responsible for the phosphorylation of βII-spectrin and adducin. Finally, while this work was under revision, Heller and colleagues showed that inhibition of PKC stabilized actin filaments in rings and the MPS as a whole, which is consistent with our findings using staurosporine (Heller et al., 2025). Finding the kinase cascade(s) targeted during the staurosporine-induced gap-and-patch pattern in human MNs could be addressed in subsequent studies. In summary, we report the discovery of a patterned MPS initiation in human MN axons, characterized by alternating βII-spectrin gaps and patches. This arrangement increases as a function of culture time and is accelerated by staurosporine in an actin-dependent manner. Our results suggest that patches represent sites of de novo MPS assembly rather than remnants of a degraded lattice. These findings provide new insights into the spatial and temporal regulation of the axonal cytoskeleton and lay the groundwork for future studies into how cytoskeletal dynamics is regulated and might be altered in neurodegenerative diseases such as ALS. Materials and methods Human iPSCs lines For this study, we used the previously validated control iPSC line AIW002-02, reprogrammed from a 37-year-old Caucasian male (Chen et al., 2021). iPSCs were cultured on Matrigel (Corning, USA)-coated 100 mm dishes (Corning) in mTeSR1 medium (STEMCELL Technologies, Canada) and passaged at ~80% confluence using Gentle Cell Dissociation Reagent (GCDR; STEMCELL Technologies). Detailed protocols for cell culture, characterization of pluripotency markers, qPCR-based assessment of chromosomal copy number, karyotyping, and virology testing are available in Chen et al., 2021. Prior to starting the experiments, iPSCs were tested weekly and confirmed to be mycoplasma-free. Differentiation of iPSCs into motor neurons AIW002-02 iPSCs were differentiated into motor neuron progenitor cells (MNPCs) as previously described (Deneault et al., 2022; Castellanos-Montiel et al., 2023; Lépine et al., 2024). After 6 days in MNPC Expansion medium (D18), cells were dissociated using GCDR and replated in MN Induction Medium containing 100 μM L-ascorbic acid (AA; Sigma-Aldrich, USA), 0.5 μM retinoic acid (RA; Sigma-Aldrich), 0.1 μM purmorphamine (Pur; Sigma-Aldrich), and 10 µM Y-27632 dihydrochloride (ROCK inhibitor; STEMCELL Technologies). After 24 h, ROCK inhibitor was removed by performing a full medium change with fresh MN Induction Medium, which was subsequently replaced every other day. After 6 days in MN Induction Medium (D21), cells were dissociated into a single-cell suspension using Accutase (Thermo Fisher Scientific, USA) and replated in the required culture vessel for each experiment, with MN Induction and Maturation Medium containing 100 μM AA, 0.5 μM RA, 0.1 μM Pur, 0.1 μM Compound E (STEMCELL Technologies), 10 ng/mL brain-derived neurotrophic factor (BDNF; PeproTech, USA), 10 ng/mL ciliary neurotrophic factor (CNTF; PeproTech), 10 ng/mL insulin-like growth factor (IGF-1; PeproTech), and 10 µM ROCK inhibitor. After 24 h, ROCK inhibitor was removed by performing a full medium change with fresh MN Induction and Maturation Medium, which was subsequently replaced once a week. MNs were used for final experiments after two weeks in MN Induction and Maturation Medium, referred to throughout the study as 2-week-old MNs. For all experiments, three independent differentiations (‘batches’) were performed using the iPSC lines for each of the four genotypes. All media were prepared in 1:1 Neurobasal:DMEM/F-12 (Thermo Fisher Scientific) supplemented with 1X Antibiotic-Antimycotic (Thermo Fisher Scientific), 0.5X N-2 (Thermo Fisher Scientific), 0.5X B-27 (Thermo Fisher Scientific), and 0.5X GlutaMAX (Thermo Fisher Scientific). Animal use and care Pregnant Wistar rats were born in the vivarium of INIMEC-CONICET-UNC (Córdoba, Argentina). Wistar rat lines were originally provided by Charles River Laboratories International Inc (Wilmington, USA). All procedures and experiments involving animals were approved by the Animal Care and Ethics Committee (CICUAL; http://www.institutoferreyra.org/en/cicual-2/) of INIMEC-CONICET-UNC (Resolution numbers 014/2017 B, 015/2017 B, 006/2017A, and 012/2017A) and were in compliance with approved protocols of the National Institute of Health Guide for the Care and Use of Laboratory Animals (SENASA, Argentina). All methods were carried out in accordance with relevant guidelines and regulations. Primary culture of rat hippocampal neurons and staining Embryonic day 18 rat embryos (euthanized by CO2 overdose) were used to prepare primary hippocampal cultures as previously described (Unsain et al., 2018a; Wilson et al., 2020). Briefly, hippocampi from 18-day fetal rats were dissected and incubated with trypsin (0.25% for 15 min at 37°C) (Thermo Fisher Gibco; Cat Number: 15090-046) and mechanically dissociated by trituration with a Pasteur pipette. Cells were plated on Cover Glasses, Circles, 12 mm (Marienfeld Superior; Cat Number: 633029) coated with 1 mg/mL poly-L-lysine (Sigma Chemical Co; Cat Number: P2636) at a density of 2000 cells/cm2 in minimum essential medium (MEM, Thermo Fisher Gibco; Cat Number: 61100-061) supplemented with CTS GlutaMAX I Supplement (Thermo Fisher Gibco; Cat Number: A1286001), sodium pyruvate (Thermo Fisher Gibco; Cat Number: 11360070), penicillin-streptomycin (Thermo Fisher Gibco; Cat Number: 15140122), and 10% horse serum (Thermo Fisher Gibco; Cat Number: 16050122). After 2 h, the coverslips were transferred to dishes containing serum-free Neurobasal (Thermo Fisher Gibco; Cat Number: 21103049) with B-27 Plus Supplement (Thermo Fisher Gibco; Cat Number: A3582801), and CTS GlutaMAX I Supplement (Thermo Fisher Gibco; Cat Number: A1286001). Neurons were fixed at 7 DIV in PFS (paraformaldehyde 4%, sucrose 4% in PBS) and stained under standard conditions with antibodies against βII-spectrin, protein 4.1N and βIII-tubulin (more details of reagents used in Appendix 1). Coverslips coating, seeding, and chemical treatment of neuronal cultures A glass coverslip (#1, Karl Hecht Assistent, Germany) was placed in each well of a 24-well plate (Corning). Each coverslip was then treated with 0.5 mL of 1X PBS (Wisent, Canada) containing 10 μg/mL poly-L-ornithine (PLO; Sigma-Aldrich). After 24 h of PLO treatment, the coverslips were washed three times with 1X PBS, followed by an overnight treatment with 0.5 mL of DMEM/F-12 containing 5 µg/mL laminin (Sigma-Aldrich). A total of 40,000 iPSC-derived MNPCs per well were plated and cultured for 14 days in final differentiation medium, after which neurons were treated with the following reagents (more details in Appendix 1): staurosporine (0.1 µM, Tocris Bioscience), L-glutamate (0.5 mM, Sigma-Aldrich), sodium arsenite (0.25 µM, Sigma-Aldrich), latrunculin A (1 µM, Cayman Chemical), ALLN-1 (5 µM, Cayman Chemical), and Caspase-3 inhibitor (zDEVD-fmk, 50 µM, R&D Systems). Immunofluorescence staining Samples were fixed for 20 min at room temperature (RT) in a fixation solution containing 4% formaldehyde (Thermo Fisher Scientific) and 4% D-sucrose (Thermo Fisher Scientific) in 1X PBS. They were then permeabilized with 0.2% Triton X-100 (Bioshop, Canada) in PBS for 5 min and blocked with two consecutive 5 min incubations in 0.1% Tween-20 (Bioshop, Canada) in PBS. Primary antibodies were incubated overnight at 4°C, followed by a 2 h incubation with secondary antibodies at RT. When used, Phalloidin (Phalloidin-Atto 647N, Sigma-Aldrich) was co-incubated with the secondary antibodies. The primary antibodies used in this study were (more details in Appendix 1): anti-βII-spectrin (BD Biosciences), anti-α-II-spectrin and anti-βIII-tubulin (BioLegend), anti-αII-tubulin (Sigma-Aldrich), anti-Cleaved-Caspase-3 (Cell Signaling), anti-βIII-tubulin, anti-4.1N, and anti-NF-H (Abcam), anti-SNTF and anti-NF-M (Millipore). Secondary antibodies were: anti-Goat anti-mouse IgG-STAR ORANGE, anti-Goat anti-rabbit IgG-STAR ORANGE, and anti-Goat anti-rabbit IgG-STAR RED (Abberior Instruments GmbH); anti-Goat anti-mouse IgG-Atto 647N (Millipore), anti-Donkey anti-chicken IgY-Alexa488 (Jackson Immunoresearch), anti-Goat anti-rat IgG-Dylight488 (Abcam). Confocal microscopy and image analysis Microscopy images were acquired at Centro de Micro y Nanoscopía de Córdoba (CEMINCO, Universidad Nacional de Córdoba, Argentina, https://ceminco.conicet.unc.edu.ar/) and at the Neuro Microscopy Core Facility (NMCF, McGill University, Canada). Confocal images were acquired using a Zeiss LSM 880 (NMCF) or a Zeiss LSM800 (CEMINCO) inverted microscope (AxioObserver platforms) equipped with a Plan-Apochromat ×63/1.40 NA oil immersion objective. Images were captured using internal photomultiplier tube (PMT) detectors and acquired through the ZEN software (version 14.0.27.201). Alexa Fluor 488, 568, and ATTO 647 dyes were sequentially excited using 488, 561, and 633 nm lasers, respectively. Emission was detected with spectral PMTs over ranges of 493–598 nm, 568–682 nm, and 638–759 nm, respectively. Pinhole diameter was set at 1.0 Airy Units. Z-stacks were acquired with an optimal step size yielding a final voxel size of 0.13 × 0.13 × 0.3 µm. Image averaging (2×) was applied during acquisition. Imaging conditions were set to avoid saturated pixels and allow observing linear changes in intensities. All imaging parameters were kept constant across conditions. Images were processed and further analyzed (as indicated below) using FIJI software (Schindelin et al., 2012), with brightness and contrast adjusted uniformly only for visualization; no further processing was applied. During image analysis, the experimenter was blinded to the group to which each image belonged. Analysis of intensity The channel with βII-spectrin was used as a reference to define the following regions of interest (ROIs) by drawing areas on patches, gaps, or the axons with continuous signal of this protein. In the latter, the sizes of areas covered about 3 μm in axon length, so as to be comparable to measures of gaps and patches. Background signal was thresholded to NaN. After that, the mean gray value was measured for every channel. Mean gray values were normalized across experiments using the mean values found in ROIs belonging to the continuous signal group in each condition. Analysis of patch length, gap length, and gap frequency Only the βII-spectrin channel was used as a reference. A segmented line was drawn along the axon; starting from a patch, each segment was measured as well as the total length of the process. These lengths were calculated using the x and y coordinates and the Pythagorean theorem. The frequency of gaps every 100 μm was then calculated. Analysis of percentage of axons with βII-spectrin gaps Whole-frame z-stacks images taken with the ×63 objective (101.21 μm × 101.21 μm) were first maximum-intensity projected. Then axons were counted as ‘with gaps’ or ‘without gaps’ in the signal of βII-spectrin if in a single axon, at least three consecutive gaps were found, forming a pattern. After that, percentages were calculated per image and normalized with the values of the control condition in a given experiment (DMSO or DMEM). Axonal length assessment αII-tubulin was evaluated. The channel was binarized with the ‘threshold’ tool and then the tool ‘skeletonize’ to convert the signal to a 1 pixel line. With the tool ‘analyze particles’, we could retrieve the total length of the skeletonized signal. After that, total length values were normalized with the values of the vehicle (DMSO or DMEM). Differential interference contrast imaging DIC images were acquired using a Confocal Olympus FV1200 inverted microscope equipped with a ×60/1.42 NA oil immersion objective and DIC optics (Nomarski prism and polarizer). Transmitted light images were acquired in DIC mode using the Olympus FV10-ASW software. The system uses internal photomultiplier detectors; no external camera was employed. Illumination settings were kept constant across conditions. Image adjustments (brightness and contrast) were applied uniformly in FIJI software (Schindelin et al., 2012) for visualization purposes; no further processing was applied. ALS knock-in iPSC lines Previous studies described the application of a streamlined CRISPR/Cas9 workflow to introduce homozygous knock-in mutations into the AIW002-02 iPSC line, generating iPSC lines with ALS-related mutations: FUSH517Q (Deneault et al., 2022), SOD1G93A and SOD1D90A/G93A (Castellanos-Montiel et al., 2023), and TDP-43A382T (Lépine et al., 2024). Here, we differentiate these validated iPSC disease lines into MNs to assess changes in the MPS following staurosporine treatment. STED nanoscopy STED nanoscopy was performed on two nanoscopes: (1) STED Quad Scan super-resolution microscope (Abberior Instruments, Germany), installed on an Olympus IX83 inverted microscope (Neuro Microscopy Core Facility, McGill University); (2) STED STEDYCON super-resolution microscope (Abberior Instruments, Germany), installed on an Olympus inverted microscope IX81 using a UPlanXApo ×100, NA:1.45, oil immersion objective (CEMINCO, Universidad Nacional de Córdoba). For single color STED, samples were excited with a 635 nm laser, and depleted with a 775 nm laser. For two-color STED, samples were excited with a 580 nm and a 635 nm laser, and depleted with a 775 nm laser. Images were obtained at a single plane, and with the pinhole open to ~1 Airy unit (more details on STED acquisitions using this instrument can be found in the supplier’s website). Briefly, pixel size was set to 10 or 15 nm, and each line was scanned three times and accumulated. Confocal excitation laser power was set on a per case basis to avoid saturated pixels in single line scans. During STED, the excitation laser was kept the same as during confocal imaging. Depletion laser power was set to the maximum allowed by the software, to obtain the maximum possible lateral resolution. Imaging conditions were kept across experimental groups belonging to the same experiment, and whole experiments were registered at once. MPS organization assessment Sampling of axonal portions to be examined STED imaging was performed in ROI of ~3 μm × ~3 μm. Selection of these was performed on the confocal signal, with no clue to the underlying nanometer organization. During organization assessment (Autocorrelation or Gollum), 1 μm segments were chosen, aiming at the most representative segment of that ROI. During image analysis, the experimenter was blinded to the group to which each image belonged. Autocorrelation amplitude analyses In each axon, 2 μm segments were chosen and fluorescence intensity profiles were extracted along the longitudinal axis of the axonal segments. These profiles were obtained from high-resolution STED images and subsequently exported to Excel for further analysis. One-dimensional autocorrelation functions were computed from the intensity data to assess spatial periodicity. The mean amplitudes of the first two autocorrelation peaks were quantified to determine the presence and regularity of the expected ~190 nm periodicity associated with the MPS. MPS organization assessment by ‘Gollum’ (Barabas et al., 2017) This open-source image analysis tool was designed for the automated quantification of the quality of protein periodic structures. Regions of interest were divided into 1 μm × 1 μm sub-regions and analyzed using the Gollum software, which is accessible at https://github.com/cibion-conicet/Gollum (Stefani Lab, 2017). Briefly, the analysis consists of interrogating systematically the presence of a given structure in images, by comparing subregions of the images to a reference pattern. For studying the MPS of MN, we first determined that control axons had a period of ~185 nm and hence the reference pattern consists of Gaussian signals with a period of 185 nm. The correlation value obtained corresponds to a two-dimensional Pearson correlation coefficient between the subregion and a modeled MPS period and is indicative of how preserved the periodic organization of the MPS is in that 1 μm section (referred to as MPS correlation coefficient). The measurement was repeated along axons in the image with no overlapping, by an operator blind to the experimental conditions. Western blot analyses For western blot analyses, cells were seeded in 6-well plates. Two-week-old MNs in MN Induction and Maturation Medium were treated with DMSO or 0.1 µM staurosporine for 1 h, then either pelleted immediately or 6 h later following a medium change. For protein extraction, cell pellets were lysed in 200 µL of ice-cold 1X RIPA buffer (Millipore, USA) containing a cocktail of protease and phosphatase inhibitors (Roche, Switzerland) and incubated for 30 min at 4℃. Every 10 min, the samples were mechanically disrupted using a pipette. Finally, the samples were centrifuged at 10,000 × g for 20 min at 4℃, and supernatants were collected for protein quantification. Protein concentration in supernatants was quantified using the DC Protein Assay (Bio-Rad, USA) according to the manufacturer’s instructions. For blotting ɑII-spectrin, βII-spectrin, and SNTF, 10 µg of protein were loaded onto a 7.5% SDS-PAGE gel and run at 70 V for 15 min, then at 120 V for ~1.5 h. Semi-dry transfer to nitrocellulose membranes was performed using the Trans-Blot Turbo Transfer System (Bio-Rad) for 10 min at 2.5 A, up to 25 V. For blotting Caspase-3 and cleaved-Caspase-3, 20 µg of protein were loaded onto a 12% SDS-PAGE gel and run at 70 V for 15 min, then at 120 V for ~1 h. Semi-dry transfer to nitrocellulose membranes was performed using the Trans-Blot Turbo Transfer System for 30 min up to 1.0 A, at 25 V. After the transfer, membranes were blocked with 5% BSA (or 5% skimmed milk [Bioshop, Canada] for Caspase-3 and cleaved-Caspase-3) in 1X TBS buffer containing 0.1% Tween 20 (blocking solution) for 1 h at RT with continuous shaking, followed by an overnight incubation with primary antibodies, diluted in their respective blocking solutions, at 4℃ with continuous shaking. After three 10 min washes with 1X TBS containing 0.1% Tween 20 (washing solution) and continuous shaking, membranes were incubated with horseradish peroxidase (HRP)-conjugated antibodies, diluted in their respective blocking solutions, for 2 h at RT with continuous shaking. After three 10 min washes with washing solution and continuous shaking, protein bands were detected using the Clarity Western ECL (Bio-Rad) (or Clarity Max Western ECL, Bio-Rad, for cleaved-Caspase-3) according to the manufacturer’s instructions and visualized using a Chemidoc MP Imaging System (Bio-Rad). Quantification was performed with the FIJI software (Schindelin et al., 2012), using β-actin as loading control. The primary antibodies used were (more details as Supplementary information): anti-βII-spectrin (BD Biosciences), anti-α-II-spectrin (BioLegend), anti-Caspase-3 and anti-Cleaved-Caspase-3 (Cell Signaling), and anti-SNTF (Millipore). And secondary antibodies were: Goat anti-mouse IgG(H+L)-HRP and Goat anti-rabbit IgG(H+L)-HRP (Jackson Immunoresearch). Statistical analyses and study design Data are presented as mean ± SEM and most graphs show also the individual values of the replicates from which the mean and SEM were calculated, as indicated in the figure legends. Calculations were made using the statistical software GraphPad Prism. Normality and homoscedasticity were proved for each group in order to apply the following parametric tests. When comparing two groups, Student’s t-test (two-tailed) was used for statistical tests. When comparisons were made among three or more groups, one-way ANOVA was used (or two-way ANOVA was used when more than one independent variable was examined); followed by Tukey post hoc multiple comparisons, to find where the differences occurred. Experiments were performed at least three times, using cells from different differentiation batches. Significance is indicated with asterisks when p≤0.05 and detailed in each case. The study design was not pre-registered. No randomization was performed to allocate subjects in the study. No sample size calculation was performed. Outliers were identified and excluded from analysis using the ROUT method (Q=1%), implemented through GraphPad Prism. This valuable study characterizes the emergence of the membrane-associated periodic cytoskeleton (MPS) in the axons of human motor neurons derived from induced pluripotent stem cells. Super-resolution imaging of beta-II spectrin provides convincing evidence for the patterned assembly of spectrin-poor gaps and spectrin-rich MPS in the medial region of the axons and its enhancement by the kinase inhibitor staurosporine. The data advocates against gap formation by axonal degeneration or cytoskeleton disassembly in a continuous MPS. Instead, a continuous MPS may result from nascent MPS patches and their maturation, a model that would benefit from live imaging for validation. The authors have presented a revised version of their investigation into the Membrane Associated Periodic Skeleton (MPS) in iPSC derived human motor neurons. As mentioned in the earlier report, the main observations reported in this article-occurrence of patch and gap arrangement of MPS-is very interesting. The real puzzle is whether, and if so how, this structure coarsens over time to produce continuous MPS. Following suggestions from reviewers, the authors attempted live cell imaging, but the results were not consistent enough and the authors point out difficulties in obtaining sufficient numbers and possible artifacts of over-expression. This investigation would have been much stronger with live cell imaging data on the dynamics of patch and gap structures. Summary: In this manuscript, Gazal et al., describe the presence of unique gaps and patches of BetaII-spectrin in medial sections of long human motor neuron axons. BII-spectrin, along with Alpha-spectrin forms horizontal linkers between 180nm spaced F-actin rings in axons. These F-actin rings along with the spectrin linkers form membrane periodic structures (MPS) which are critical for maintenance of the integrity, size and function of axons. The primary goal of the authors was to address if long motor axons, particularly those carrying familial mutations associated with the neurodegenerative disorder ALS, show defects in gaps and patches of BetaII-spectrin ultimately leading to degradation of these neurons. Strengths: The experiments are well designed and the authors have used the right methods and cutting-edge techniques to address the questions in this manuscript. The use of human motor neurons and the use of motor neurons with different familial ALS mutations is a strength. The use of isogenic controls is a positive. The induction of gaps and patches by the kinase inhibitor staurosporine and their rescue by Latrunculin A is novel and well executed. The use of biochemical assays to explore the role of calpains is appropriate and well designed. The use of STED imaging to define the periodicity of MPS in the gaps and patches of spectrin is a strength. Weaknesses: Primary weakness is the lack of rigorous evaluation to validate the proposed model of spectrin capture from the gaps into adjacent patches by the use of photobleaching and live-imaging. Another point is the lack of investigation into how gaps and patches change in axons carrying the familial ALS mutations as they age, since 2 weeks is not a timepoint when neurodegeneration is expected to start. Comment on revised version. The authors have given a point-by-point response to all the reviewer's concerns. They have also addressed concerns which I raised adequately. I have no further concerns. Summary: Gazal et al present convincing evidence supporting a new model of MPS formation where a gap-and-patch MPS pattern coalesces laterally to give rise to a lattice covering the entire axon shaft. Strengths: (1) This is a very interesting study that supports a change in paradigm in the model of MPS lattice formation. (2) Knowledge on MPS organization is mainly derived from studies using rat hippocampal neurons. In the current manuscript, Gazal et al use human IPS-derived motor neurons, a highly relevant neuron type to further the current knowledge on MPS biology. (3) The quality of the images provided, specifically of those involving super-resolution is of high standards, supporting adequately the conclusions of the authors. Weaknesses: (1) The main concern raised by the manuscript is the assumption that staudosporine-induced gap and patch formation recapitulates the physiological assembly of gaps and patches of betaII-spectrin. (2) One technical challenge that limits a more compelling support of the new model of MPS formation, is that fixed neurons are imaged, which precludes the observation of patch coalescence. The following is the authors’ response to the original reviews. eLife Statement This valuable study characterizes the emergence of the membrane-associated periodic cytoskeleton (MPS) in the axons of human motor neurons derived from induced pluripotent stem cells. Super-resolution imaging of beta-II spectrin provides convincing evidence for the patterned assembly of spectrin-poor gaps and spectrin-rich MPS in the medial region of the axons and its enhancement by the kinase inhibitor staurosporine. The data advocates against gap formation by cytoskeleton disassembly in a continuous MPS. Instead, a continuous MPS may result from nascent MPS patches and their maturation, a model that would benefit from live imaging for validation. (R1) We thank the reviewers and editor for their constructive and thoughtful feedback. We are pleased the reviewers found our evidence to be convincing and that our study provides a valuable framework for understanding the complex dynamics of MPS assembly. Public Reviews: Reviewer #1 (Public review): Summary: Ever since the surprising discovery of the membrane-associated Periodic Skeleton (MPS) in axons, a significant body of published work has been aimed at trying to understand its assembly mechanism and function. Despite this, we still lack a mechanistic understanding of how this amazing structure is assembled in neuronal cells. In this article, the authors report a "gap-and-patch" pattern of labelled spectrin in iPSC-derived human motor neurons grown in culture. The mid-sections of these axons exhibit patches with reasonably well-organized MPS that are separated by gaps lacking any detectable MPS and having low spectrin content. Further, they report that the intensity modulation of spectrin is correlated with intensity modulations of tubulin as well. However, neurofilament fluorescence does not show any correlation. Using DIC imaging, the authors show that often the axonal diameter remains uniform across segments, showing a patch-gap pattern. Gaps are seen more abundantly in the midsection of the axon, with the proximal section showing continuous MPS and the distal segment showing continuous spectrin fluorescence but no organized MPS. The authors show that spectrin degradation by caspase/calpain is not responsible for gap formation, and the patches are nascent MPS domains. The gap and patch pattern increases with days in culture and can be enhanced by treating the cells using the general kinase inhibitor staurosporine. Treatment with the actin depolymerizing agent Latrunculin A reduces gap formation. The reasons for the last two observations are not well understood/explained. (R2) We thank the reviewer for the detailed and accurate description of the data shown and its relevance to further our understanding of MPS assembly mechanism and function. Strengths: The claims made in the paper are supported by extensive imaging work and quantification of MPS. Overall, the paper is well written and the findings are interesting. Although much of the reported data are from axons treated with staurosporine, this may be a convenient system to investigate the dynamics of MPS assembly, which is still an open question. (R3) We thank the reviewer for the positive comments on the manuscript and the convenience of the experimental system developed to further study the dynamics of MPS assembly. We hope others turn into motor neurons to explore cortical cytoskeleton biology and hopefully shed light into their susceptibility in various degenerative diseases. Weaknesses: Much of the analysis is on staurosporine-treated cells, and the effects of this treatment can be broad. The increase in patch-gap pattern with days in culture is intriguing, and the reason for this needs to be checked carefully. It would have been nice to have live cell data on the evolution of the patch and gap pattern using a GFP tag on spectrin. The evolution of individual patches and possible coalescence of patches can be observed even with confocal microscopy if live cell super-resolution observation is difficult. (R4) Because staurosporine may hit various kinases relevant to the phenomenon under study we did not elaborate too deeply on the likely targets in the discussion. We have, however, included the possibility that the relevant kinase in this matter could be PKC, in light of the new study published while our manuscript was under revision (Heller et al., 2025) (see second last paragraph in the Discussion section). Staurosporine represented a convenient initial approach that allowed us to find the phenomenon, and we are now conducting new studies dissecting the molecular pathways involved. However, the extent of such studies lies beyond the scope of the present report. See R16 regarding possible live-imaging experiments using tagged βII-spectrin constructs. Some more comments: (1) Axons can undergo transient beading or regularly spaced varicosity formation during media change if changes in osmolarity or chemical composition occur. Such shape modulations can induce cytoskeletal modulations as well (the authors report modulations in microtubule fluorescence). The authors mention axonal enlargements in some instances. Although they present DIC images to argue that the axons showing gaps are often tubular, possible beading artefacts need to be checked. Beading can be transient and can be checked by doing media changes while observing the axons on a microscope. (R5) As we acknowledge this possibility, we believe that, even if they occurred, they could not contribute to our observations of gaps-and-patches phenomenon since this latter subsisted long (hours and days) after any gross manipulation of media. Moreover fixed samples, when observed under DIC, confocal or STED did not evidence such beadings. We do refer to a characteristic local enlargement that was very localized and very low in numbers (see Fig.1C and E, and Suppl. Fig1C and E), so we don't believe these are transient, and do not resemble the structure referred to as beading. Structurally, beading is essentially different since it appears in rows of consecutive “beads” in long stretches, where round, small enlargements of axonal caliber are arranged in a consecutive manner, resembling pearls on a string. As mentioned by the reviewer, the beading phenomena can occur transiently when drastically changing media osmolarity (rarely done in cell culture manipulations) or non-tranciently when axons are undergoing degeneration. Indeed, to prevent gross changes in osmolarity, our routine fixation is a 4% PFA and 4% sucrose in PBS. In any case, we did not observe signs of beading in the cultures used for this study. (2) Why do microtubules appear patchy? One would imagine the microtubule lengths to be greater than the patch size and hence to be more uniform. (R6) Our stainings are for tubulin protein isoforms beta-III and alpha-II. That is, they would label microtubules, but free tubulin as well. Hence we don't think this is evidence for “patchy microtubules”. The slight decrease in intensity for tubulin within gaps is indeed something to investigate, and can indicate that tubulin prefers to accumulate within patches. (3) Why do axons with gaps increase with days in culture? If patches are nascent MPS that progressively grow, one would have expected fewer gaps with increasing days in culture. Is this indicative of some sort of degeneration of axons? (R7) We agree with the apparent discrepancy. However, one has to take into account that these axons are still elongating even at 2 weeks in culture and beyond. Hence, at any time point, there is a new axonal compartment recently added, and hence, with low βII-spectrin and no organized MPS. Also, the dynamical evolution of the gaps-and-patches structure has to take into account the rate of βII-spectrin supply and transport. If supply is somehow lower than a given threshold, it is expected that there will be more gaps, given the new, more distant parts of the axons have a lower supply of βII-spectrin. To explore this formally, we are working on simulations of these multifactorial dynamic systems to better understand this, that together with key experimental observations would enhance our understanding into our model of MPS assembly in growing axons. However, findings for this project will be the subject of another manuscript. (4) It is surprising that Latrunculin A reduces gap formation induced by staurosporine (also seems to increase MPS correlation) while it decreases actin filament content. How can this be understood? If the idea is to block actin dynamics, have the authors tried using Jasplakinolide to stabilize the filaments? (R8) The results with the co-treatment with Latrunculin A and Staurosporine are indeed intriguing, and provide clear evidence that the gap-and-patch pattern arises from local assembly of the MPS, requiring newly formed actin filaments. On the other hand, the fact that F-actin within the pre-formed MPS seems unaffected is not surprising. There are many different populations of F-actin in axons (i.e. MPS rings, longitudinal filaments, actin patches, actin trails), all of which have a different rate of monomer turnover. Latrunculin A affects filaments indirectly. The target of Latrunculin A is not actin filaments, but free monomers. Monomer sequestration ultimately affects actin filaments: filaments are constantly exchanging monomers, but, devoid of free monomers, filaments get shorter and eventually disappear. The drastic decrease in global F-actin in LatA-treated axons reflects that. The fact that F-actin in the MPS is preserved shows that these filaments are stable -if they are not losing monomers in the time frame of the treatment, the filament remains unaffected. This subject is extensively covered in the 8th paragraph of the Discussion section. We have not used Jasplakinolide. The expected outcome will not mimic that of Latrunculin A since Jasplakinolide has a different mechanism of action (i.e. it binds -and stabilizes- the actin filament). (5) The authors speculate that the patches are formed by the condensation of free spectrins, which then leaves the immediate neighborhood depleted of these proteins. This is an interesting hypothesis, and exploring this in live cells using spectrin-GFP constructs will greatly strengthen the article. Will the patch-gap regions evolve into continuous MPS? If so, do these patches expand with time as new spectrin and actin are recruited and merge with neighboring patches, or can the entire patch "diffuse" and coalesce with neighboring patches, thus expanding the MPS region? (R9) We agree with the reviewer's interpretation. A virtue of our experimental model and our interpretations of the observations in fixed cells is that it gives rise to informative questions such as the ones posed by the reviewer. See R16 regarding possible live-imaging experiments using tagged βII-spectrin constructs. Reviewer #2 (Public review): Summary: In this manuscript, Gazal et al. describe the presence of unique gaps and patches of BetaII-spectrin in medial sections of long human motor neuron axons. BII-spectrin, along with Alpha-spectrin, forms horizontal linkers between 180nm spaced F-actin rings in axons. These F-actin rings, along with the spectrin linkers, form membrane periodic structures (MPS) which are critical for the maintenance of the integrity, size, and function of axons. The primary goal of the authors was to address whether long motor axons, particularly those carrying familial mutations associated with the neurodegenerative disorder ALS, show defects in gaps and patches of BetaII-spectrin, ultimately leading to degradation of these neurons. (R10) We thank the reviewer for the detailed and accurate description of the data shown. Strengths: The experiments are well-designed, and the authors have used the right methods and cutting-edge techniques to address the questions in this manuscript. The use of human motor neurons and the use of motor neurons with different familial ALS mutations is a strength. The use of isogenic controls is a positive. The induction of gaps and patches by the kinase inhibitor staurosporine and their rescue by Latrunculin A is novel and well-executed. The use of biochemical assays to explore the role of calpains is appropriate and well-designed. The use of STED imaging to define the periodicity of MPS in the gaps and patches of spectrin is a strength. (R11) We thank the reviewer for the positive comments on the manuscript, the techniques used and the proposed model. Weaknesses: The primary weakness is the lack of rigorous evaluation to validate the proposed model of spectrin capture from the gaps into adjacent patches by the use of photobleaching and live imaging. Another point is the lack of investigation into how gaps and patches change in axons carrying the familial ALS mutations as they age, since 2 weeks is not a time point when neurodegeneration is expected to start. (R12) See R16 regarding possible live-imaging experiments using tagged βII-spectrin constructs. We don't discard the notion that axons carrying familial ALS mutations will show defects in MPS formation and/or stability when observed at longer culture times, or under culture conditions that promote neuronal aging (Guix et al., 2021). Thus, we continue to work with these cells, but the goal of such project lies well beyond the primary message of the present manuscript, as we discuss in the second paragraph of the Discussion section. Reviewer #3 (Public review): Summary: Gazal et al present convincing evidence supporting a new model of MPS formation where a gap-and-patch MPS pattern coalesces laterally to give rise to a lattice covering the entire axon shaft. Strengths: (1) This is a very interesting study that supports a change in paradigm in the model of MPS lattice formation. (2) Knowledge on MPS organization is mainly derived from studies using rat hippocampal neurons. In the current manuscript, Gazal et al use human IPS-derived motor neurons, a highly relevant neuron type, to further the current knowledge on MPS biology. (3) The quality of the images provided, specifically of those involving super-resolution, is of a high standard. This adequately supports the conclusions of the authors. (R13) We thank the reviewer for the positive comments on the manuscript, the techniques used and the proposed model. Weaknesses: (1) The main concern raised by the manuscript is the assumption that staudosporine-induced gap and patch formation recapitulates the physiological assembly of gaps and patches of betaII-spectrin. (R14) Along the project, various gaps-and-patches parameters were measured in different conditions and stainings. In all these examinations the only parameter that changed considerably was their abundance. While this suggests that the gaps-and-patches features are comparable between control and staurosporine-treated cells, we acknowledge as a general caution regarding negative data—that subtle qualitative differences cannot be entirely ruled out. We have now emphasized this possibility in the 9th paragraph of the Discussion section. (2) One technical challenge that limits a more compelling support of the new model of MPS formation is that fixed neurons are imaged, which precludes the observation of patch coalescence. (R15) See R16 regarding possible live-imaging experiments using tagged βII-spectrin constructs. Recommendations for the authors: Reviewing Editor Comments: The reviewers all agree that the work would strongly benefit from live imaging to assess the maturation dynamics of the gap/patch pattern. (R16) Reviewers agreed that some of the conclusions of our manuscript would benefit from live imaging for validation. Various anticipated technical and biological challenges made these approaches not to be conducted for this initial study on human motor neurons. Just to mention the most important, from previous work of our labs, these cells themselves are difficult to transfect at 2 weeks in culture. Also, ectopically expression of tagged βII-spectrin escapes normal expression control and it has been noticed that ectopic expression yields to protein localization that does not necessarily reflect the endogenous distribution, or that produces cellular responses that precludes the observation of the phenomena under study. These difficulties in studying over-expressed tagged βII-spectrin have been reported in the field, with mentions that the analysed axons were those expressing “low levels of the construct” (Boyer et al., 2026; Zhong et al., 2014; Zhou et al., 2022). Taking this into account, we did not anticipate that, for the goals of the present project, live-imaging was to be included. However, given the positive comments and reception of our conclusions, we sought to try to perform this challenging and risky approach. To that end, we used a C-terminus tagged mouse βII-spectrin-GreenLantern plasmid to transfect our cells (a kind gift from Dr. Subjohit Roy, UCSD, USA). After 3 rounds of differentiating cells and trying various combinations of plasmid quantity, lipofectimine-to-DNA ratios and times of transfection (amongst other parameters), we have got an extremely low efficiency of transfection, and the few expressing neurons showed a distribution of βII-spectrin-GreenLantern that did not match our observations of immunolocalization of endogenous βII-spectrin. Taking all these into account, the present version of the manuscript will not include live-cell imaging on expressed tagged βII-spectrin. Given that reviewers found that some statements in the initial submission would have been better supported by live-imaging, we made changes in the manuscript so as to acknowledge the limitations of concluding dynamic mechanisms from fixed samples (see for example last sentences on 5th paragraph of the Discussion section). Having said so, we hope to be able, in the future, to overcome these experimental challenges and be able to establish live-imaging of βII-spectrin in neurons. For example, to avoid unregulated transgene expression, Heller and colleagues recently generated a βII- spectrin-mNeonGreen conditional knock-in (cKI) mice, consisting of a LoxP- flanked alternative final exon of endogenous βII-spectrin with a C- terminal mNeonGreen fusion that is expressed upon Cre expression (Heller et al., 2025). The implementation and further development of such approaches will be very helpful in new studies on the dynamics of βII-spectrin and the MPS as a whole. However, the scale of work needed to accomplish those approaches represent stand-alone projects. Reviewer #1 (Recommendations for the authors): In the section "The MPS is absent in beta-II spectrin gaps, the authors mention that the presence of MPS in patches suggests that the axons are not undergoing degeneration. I don't think this is a good criterion to use, despite the citations they take support from. (R17) We agree with the reviewer's suggestion: in virtue of the unlikely connection between the cited developmental axon degeneration process in sensory neurons and the possible axon degeneration of long term cultures of human-iPSCs-derived motor neurons studied here, we have eliminated the sentence of reference The authors show that degradation by proteases does not happen in their case. In this regard, they may want to discuss the recent article by Heller et al, Science 2025 (https://doi.org/10.1126/science.adn6712) and Hofmann et al, Sci. Rep., 2022 (https://doi.org/10.1038/s41598-022-18562-5) (R18) By western blot analysis, we did not see evident changes in proteolysis-derived fragments. However it is likely that even when finding phenotypes with protease inhibitors, protein fragments accumulation is below the sensitivity of western blots. We were expecting gross changes observable by western blot in the case proteolysis explained gap formation. Calpain and Caspase activity has been shown to be relevant in different aspects of MPS biology. To the works cited by the reviewer, now one has to add the very recent work by Fei and colleagues (Fei et al., 2026). We have modified part of the Discussion section to analyse our results in this broader context. Briefly, Hofmann and colleagues found that acute treatment with calpain inhibitors right before axotomy lead to an increase in percentage of periodic βII-spectrin (referred by authors as “periodicity”) in the regenerated axons in a 2-hour period. Interestingly, the βII-spectrin patches they describe at distal portions did not increase in number, but they increased in size. This indicates that in the particular situation of axonal regeneration calpain activity puts a brake into MPS formation within patches. This invited us to re-examine our own protease inhibition experiments, and measured patch length in this. The new results are shown in Supplementary Fig. 6 and further analysed in the Discussion section. In summary, our changes were much less notable than the ones found in regenerating axons, but follow the same trend: protease inhibitors made patches longer. On the other hand, Heller and colleagues found in live-imaging studies that calpain activity contributes to the steady-state dynamics of βII-spectrin exchange in a mature MPS lattice. More recently, Fei and colleagues found that caspase or calpain inhibition does not change the steady-state organization of a mature MPS lattice when observing treated axons after fixation samples. Fei and colleagues find a relevant role for calpains whenever massive endocytosis (of any kind) is engaged experimentally. Interestingly, all these studies, including ours, examined calpains roles in MPS in different scenarios. When looked in detail, we don’t believe that these are contradictory results among them, and a complete picture of calpains (and caspases) roles in MPS assembly, growth, maintenance and remodeling will have to take into account all the above mentioned results, including ours. All these analyses are now included in the Discussion section. Minor comments: (1) "Recently, it was proposed that this continuous MPS organization arises from the coalescence of discontinuous "patches" of incomplete MPS units that originate in the distal axon and migrate proximally (Zhong et al. 2014)." Please check the citation. Should it be Hoffman et al. 2022? (R19) The reviewer is correct. The proper citation has now been included. (2) Is there an established link between ALS and spectrin? I would suggest decreasing the emphasis on this as no clear conclusions are achieved. (R20) As stated in the text, the study of ALS mutations is justified from two aspects: one aspect is that there are several tubulin and other cytoskeletal proteins whose mutations are linked to ALS (Castellanos-Montiel et al., 2020) and microtubules dynamics has been shown to affect the cortical skeleton (Qu et al., 2017). Second, since human motor neurons are affected in ALS, we thought that a complete characterization of the βII-spectrin cortical cytoskeleton in these cells should include ALS-related mutations. We have now included an a basic MPS description in TDP43 and SOD1 mutation (Suppl. Fig. 5). The aspect of ALS-related mutations only occupies two short paragraphs in the main text and some panels in Supplementary information. To follow the suggestions by the Reviewer, we have downplayed the relative relevance of these results in the text, without compromising the amount of data we show. (3) There is a typo in the approximate symbol used for 150 kDa in the section where calpain and caspase activity is reported. (R21) Typo corrected. (4) Please add the Latrunculin concentration used in the main text, as it makes it easier for the reader. (R22) Done. (5) In the Discussion, paragraph starting with "We further showed ...", there is a typo where Zhong et al is cited. (R23) Corrected. (6) Supplementary Figure 1B: attachment instead of 'atachment'. (R24) Corrected. (7) Include DIVs or time in the schematic. It is easier for the reader to understand. (R25) We have now included time references in schematics of Suppl. Fig1B. (8) Supplementary Figure 1C Unable to distinguish βII-spectrin and βIII-tubulin in the merged image. Separate figure panels will help. (R26) The merged images in the reconstructions are merely to better show the tracing individual axons at such low magnification. Relevant portions with only βII-spectrin channels are shown in C1 and C2. Separated individual channels are shown elsewhere across the manuscript. (9) Supplementary Figure 4D Why is there so much cleavage product for αII-spectrin across DMSO and treatment? It varied over batches as well. Doesn't this mean that αII-spectrin is going through more proteolytic cleavage? Why? (R27) The amount of cleavage product for αII-spectrin is not a surprise to us. For instance, although calpains and caspases can potentially process both α- and β-spectrin, in in vivo scenarios where calpain activity is triggered there are much more fragments of α-spectrin being produced (Czogalla & Sikorski, 2005). On the other hand, our staining of cleaved-αII-spectrin by the SNTF antibody by immunofluorescence (Fig4C) parallels the findings by western blot -high levels of cleaved-αII-spectrin across treatments. A similar strong staining using this antibody has been recently shown in the intact axon (Heller et al., 2025). It will be interesting in the future to address if these fragments have any biological significance beyond being mere byproducts of αII-spectrin processing. Reviewer #2 (Recommendations for the authors): Suggestions for improving the quality of the manuscript: (1) Live imaging in combination with FRAP assays will help define whether the capture of spectrin from gaps into patches is true. Fixed neurons only provide static information and may not reflect real-time physiological effects. (R28) See R16 regarding possible live-imaging experiments using tagged βII-spectrin constructs. (2) Could the presence of F-actin trails in axons facilitate the formation of patches? Will the use of formin/Arp2/3 inhibitors rescue the effect of staurosporine, similar to Latrunculin A? (R29) Very interesting suggestion. It is likely that different pools of F-actin contribute to the dynamic of MPS formation, and actin trails are definitely worth investigating in this context. (3) Figure 8 lacks a latrunculin A treated condition? Why is this not present? (R30) The quantification of that treatment was excluded for space and readability. We have now included the values of group LatA + DMSO in Fig8Cand D and rearranged the whole figure. (4) Does neuronal stimulation have any effect (KCl treatment) on gaps and patches? (R31) Very interesting suggestion. Unfortunately, we have not examined whereas neuronal stimulation affects any parameter of the gaps-and-patches structure. (5) Please check the manuscript for typos and reference insertion points in the text. More than a couple were noted. (R32) We have corrected typos. Reviewer #3 (Recommendations for the authors): This is a very interesting study that supports a change in paradigm in the model of MPS lattice formation. (1) One major concern is the assumption that staudosporine-induced gap and patch formation recapitulates the physiological assembly of gaps and patches of betaII-spectrin, solely based on their morphological similarity. This should be further discussed in the manuscript. Further analysis of additional cytoskeleton components, including microtubules in staurosporine-treated neurons, could also be provided. (R33) See R14. (2) In Figure 1E, betaIII-tubulin and NF-H seem to accumulate in betaII-spectrin-rich axonal enlargements. If these are patches, how do you reconcile this finding with Figure 2C-D, where NF-M and alphaII-tubulin are not specifically enriched in betaII-spectrin patches? (R34) We actually show that axonal enlargements and patches are structurally unrelated, in many aspects. We mention these axonal enlargements as a way to perform an exhaustive characterization of all βII-spectrin features found in these axons. (3) One technical challenge that limits a more compelling support of the new model of MPS formation is that fixed neurons are imaged, which precludes the observation of patch coalescence. This should be further discussed in the revised version of the manuscript. (R35) The limitation of the experimental approach is now further discussed (see for example last sentences on 5th paragraph of the Discussion section). (4) On a more general note, the title of some of the Results sub-sections could be revised to convey the findings of those sub-sections and not the Methods that were used (example: "Quantitave and Qualitative analyses of betII-spectrin distribution...."). (R36) According to the suggestion, we have changed the title of this subsection. References Boyer, N. P., Sharma, R., Wiesner, T., Parperis, C., Delamare, A., Pelletier, F., Jullien, N., Bhatt, A. M., Parra-Rivas, L. A., Kearney, P. J., Shavarebi, F., Leterrier, C., & Roy, S. (2026). Spectrin condensates provide a nidus for assembling the axonal membrane-associated periodic skeleton. iScience, 29(1), 114454. https://doi.org/10.1016/j.isci.2025.114454 Castellanos-Montiel, M. J., Chaineau, M., & Durcan, T. M. (2020). The Neglected Genes of ALS: Cytoskeletal Dynamics Impact Synaptic Degeneration in ALS. Frontiers in Cellular Neuroscience, 14, 594975. https://doi.org/10.3389/fncel.2020.594975 Czogalla, A., & Sikorski, A. F. (2005). Spectrin and calpain: A “target” and a “sniper” in the pathology of neuronal cells. Cellular and Molecular Life Sciences: CMLS, 62(17), 1913–1924. https://doi.org/10.1007/s00018-005-5097-0 Guix, F. X., Capitán, A. M., Casadomé-Perales, Á., Palomares-Pérez, I., López Del Castillo, I., Miguel, V., Goedeke, L., Martín, M. G., Lamas, S., Peinado, H., Fernández-Hernando, C., & Dotti, C. G. (2021). Increased exosome secretion in neurons aging in vitro by NPC1-mediated endosomal cholesterol buildup. Life Science Alliance, 4(8), e202101055. https://doi.org/10.26508/lsa.202101055 Heller, E., Kurup, N., & Zhuang, X. (2025). The membrane skeleton is constitutively remodeled in neurons by calcium signaling. Science (New York, N.Y.), 389(6760), eadn6712. https://doi.org/10.1126/science.adn6712 Qu, Y., Hahn, I., Webb, S. E. D., Pearce, S. P., & Prokop, A. (2017). Periodic actin structures in neuronal axons are required to maintain microtubules. Molecular Biology of the Cell, 28(2), 296–308. https://doi.org/10.1091/mbc.E16-10-0727 Zhong, G., He, J., Zhou, R., Lorenzo, D., Babcock, H. P., Bennett, V., & Zhuang, X. (2014). Developmental mechanism of the periodic membrane skeleton in axons. eLife, 3, e04581. https://doi.org/10.7554/eLife.04581 Zhou, R., Han, B., Nowak, R., Lu, Y., Heller, E., Xia, C., Chishti, A. H., Fowler, V. M., & Zhuang, X. (2022). Proteomic and functional analyses of the periodic membrane skeleton in neurons. Nature Communications, 13(1), 3196. https://doi.org/10.1038/s41467-022-30720-x